Photo of Clinical Research Volunteers
Office of the Vice President for Research
FindAStudy :: Human Studies @ UTHSCSA
281  Studies 109  Researchers 27  Categories
× Server Error: Please contact a VPR IT team member for assistance.
× Result: 161 studies found using "cancer"
No studies found - try again with different search terms.
Choose a Category Below to Show a List of Study Titles
  •   Cancers and Other Neoplasms

    •   Bones and joints

      •   AEWS07B1, A COG Study for Collecting and Banking Ewing Sarcoma Specimens
        Protocol No.
        HSC20090244X
        Official Title
        AEWS07B1, A COG Study for Collecting and Banking Ewing Sarcoma Specimens
        Description
        This research study is collecting and storing samples of tumor tissue, bone marrow, and blood from patients with Ewing sarcoma. Collecting and storing samples of tumor tissue, bone marrow, and blood from patients with cancer to test in the laboratory may help the study of cancer in the future.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AEWS1031 A Phase III Randomized Trial of Adding...
        Protocol No.
        HSC20110367X
        Official Title
        AEWS1031 A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
        Description
        This randomized phase III trial studies combination chemotherapy to see how well it works compared to combination chemotherapy with topotecan hydrochloride in treating patients with non-metastatic extracranial Ewing sarcoma. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, etoposide, and topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective with topotecan hydrochloride in treating Ewing sarcoma.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AEWS1221 - Randomized Phase II Trial Evaluating the Addition of the IGF-1R...
        Protocol No.
        HSC20150360X
        Official Title
        AEWS1221 - Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma An Intergroup NCTN Phase II Study
        Description
        Primary Objective: To compare the event-free survival (EFS) in patients with newly diagnosed metastatic Ewing sarcoma treated with multiagent chemotherapy with and without the addition of ganitumab (AMG 479). Secondary Objective: To describe the toxicity of the addition of ganitumab to multimodality therapy for patients with newly diagnosed metastatic Ewing sarcoma. Exploratory Objectives: 1) To compare bone marrow response rates and overall survival in patients with newly diagnosed metastatic Ewing sarcoma treated with multiagent chemotherapy with and without the addition of ganitumab. 2) To describe the toxicity of 6 months of ganitumab monotherapy as Maintenance therapy following multimodality therapy in patients with newly diagnosed metastatic Ewing sarcoma. 3) To describe trough levels of ganitumab in a cohort of patients with Ewing sarcoma < 21 years of age treated with 18 mg/kg. 4) To describe the feasibility of and local failure rates following hypofractionated stereotactic body radiotherapy (SBRT) directed at bone metastases in patients with newly diagnosed metastatic Ewing sarcoma. 5) To determine if EFS, overall survival, bone marrow response rates, and toxicity differ based on serum markers of the IGF-1 pathway in patients with newly diagnosed metastatic Ewing sarcoma treated with interval compressed chemotherapy with and without the addition of ganitumab. 6) To determine if EFS, overall survival, and bone marrow response rates differ based on tumor IGF-1R, insulin receptor, and EGFR pathway components in patients with newly diagnosed metastatic Ewing sarcoma treated with interval compressed chemotherapy with and without the addition of ganitumab. 7) To evaluate bone marrow micrometastatic disease and tumor cell surface IGF-1R expression at diagnosis and after 3 and 6 cycles of study therapy in patients with newly diagnosed metastatic Ewing sarcoma. 8) To determine if the presence of germline polymorphisms in EGFR correlate with response to multiagent therapy with and without ganitumab. 9) To investigate the ability of FDG-PET to augment conventional response assessment of primary Ewing sarcoma tumors by MRI. 10) To explore FDG-PET response at the primary tumor as a prognostic marker and as a predictive biomarker of clinical activity of IGF-1R inhibition in patients with newly diagnosed metastatic Ewing sarcoma.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AOST06B1 A Children''s Oncology Group Protocol for Collecting and Banking...
        Protocol No.
        HSC20090245X
        Official Title
        AOST06B1 A Children''s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens
        Description
        RATIONALE: Collecting and storing samples of tumor tissue and blood from patients to test in the laboratory may help the study of cancer in the future. PURPOSE: The purpose of this study is to collect and store samples of blood and tumor tissue from patients with osteosarcoma.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AOST1321 - Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK...
        Protocol No.
        HSC20160209X
        Official Title
        AOST1321 - Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma. An Intergroup NCTN Phase 2 Study
        Description
        Primary Aims 1.1.1 To determine whether denosumab therapy either increases the disease control rate at 4 months in patients with recurrent measurable osteosarcoma as compared to historical COG experience or denosumab therapy produces an objective response rate greater than 5% (Cohort 1). 1.1.2 To determine whether denosumab therapy increases the disease control rate at 12 months in patients with recurrent resected osteosarcoma as compared to historical COG experience (Cohort 2). Secondary Aims 1.2.1 To investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of denosumab in subjects with recurrent osteosarcoma. 1.2.2 To describe the tolerability of denosumab in subjects with recurrent osteosarcoma. 1.2.3 To report the disease control rate and objective response rate for patients with recurrent osteosarcoma limited to bone. 1.2.4 To investigate biological markers potentially associated with response to denosumab in patients with recurrent osteosarcoma.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AOST1421, A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside...
        Protocol No.
        HSC20160053XT
        Official Title
        AOST1421, A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC#764038, IND# 4308) in Combination with GM-CSF in Patients with Recurrent Osteosarcoma
        Description
        1.1 Primary Aims To determine the disease control rate in patients with completely resected recurrent osteosarcoma treated with ch14.18 (dinutuximab) in combination with sargramostim (GM-CSF) as compared to historical COG experience. 1.2 Secondary Aims 1.2.1 To characterize the pharmacokinetics of ch14.18 (dinutuximab) in patients with recurrent osteosarcoma in the proposed administration schedule. 1.2.2 To determine the occurrence of unacceptable toxicity (UT) in patients with recurrent osteosarcoma treated with ch14.18 (dinutuximab) in combination with sargramostim. 1.3 Exploratory Aims 1.3.1 To assess the relationship between probability of disease control and tumor GD2 expression. 1.3.2 To attempt banking of tumor samples for future research studies from patients enrolled on study who undergo biopsy or resection of suspected metastatic disease recurrence while on protocol therapy or during the evaluation period. 1.3.3 To assess KIR and FcyR genotypes NKp30 isoforms and its circulating ligand, B7-H6 and their relatiobships to the probability of disease control. 1.3.4 To determine a descriptive profile of human anti-chimeric antibody (HACA) during immunotherapy.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Brain & Nervous System

      •   A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum...
        Protocol No.
        HSC20140450X
        Official Title
        A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes (RNL) in Recurrent Glioblastoma (CTRC# 12-02)
        Description
        While radiation is an essential component to the treatment of glioblastoma, it''s use is limited due to toxicity when higher doses are attempted. Rhenium is a compund which releases radiation in small particles that are absorbed after only a fraction of an inch. This limited penetration means that high doses potentially can be given without the toxicity of other forms of radiation. In order for the radiaiton to be retained within the tumor, it has been packaged in microscopic fat like particles termed nanoliposomes. These facilitate the uptake of the radiation particles by the tumor. In order to better characterize this form of radiation therapy, it is being administered in patients who have failed other forms of therapy for glioblastoma. The treatment is administered by tubing inserted into the center of the tumor in the operating room. There are two portionms to this study. The first involves progressively increasing doses until the most tolerable dose can be identified. The second portion of the study involves a larger number of patients being treated at the determined most tolerable dose to better evalaute how well the treatment works.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety...
        Protocol No.
        HSC20170090HU
        Official Title
        A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety of TVB-2640 in Combination with Bevacizumab in Patients with First Relapse of High Grade Astrocytoma (CTMS# 16-0136)
        Description
        Primary Objective(s): To determine if the progression-free survival of patients with High Grade Astrocytoma who are treated with TVB-2640 in combination with bevacizumab is superior to treatment with bevacizumab alone. Secondary Objective(s): To evaluate the safety of TVB-2640 in combination with bevacizumab in patients with High Grade Astrocytoma. Exploratory Objective: To determine the extent by which TVB-2640 is able to penetrate the blood brain barrier where it might have the opportunity to affect tumor tissue metabolism.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ACCL10P1 - Computerized Cognitive Training for Pediatric Brain Tumor...
        Protocol No.
        HSC20140435X
        Official Title
        ACCL10P1 - Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study A Limited-Institution Pilot Study
        Description
        This randomized clinical trial studies how well an adaptive computerized cognitive training program works compared to a non-adaptive computerized cognitive training program in treating younger patients with brain tumor who underwent radiation therapy. Providing a computer training program may improve the well-being and quality of life of patients with cognitive (physical and mental) function difficulties caused by radiation therapy to the brain.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ACNS02B3: A CHILDREN''S ONCOLOGY GROUP PROTOCOL FOR COLLECTING AND BANKING...
        Protocol No.
        HSC20040266H
        Official Title
        ACNS02B3: A CHILDREN''S ONCOLOGY GROUP PROTOCOL FOR COLLECTING AND BANKING PEDIATRIC BRAIN TUMOR RESEARCH SPECIMENS
        Description
        he purpose of this study is to collect and store brain tissue samples and blood from children with brain cancer that will be tested in the laboratory. Collecting and storing samples of tumor tissue and blood from patients to test in the laboratory may help the study of cancer in the future.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ACNS0831 Phase III Randomized Trial of Post-Radiation Chemotherapy in...
        Protocol No.
        HSC20110258X
        Official Title
        ACNS0831 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
        Description
        This randomized phase III trial is studying maintenance chemotherapy to see how well it works compared to observation following induction chemotherapy and radiation therapy in treating young patients with newly diagnosed ependymoma. Drugs used in chemotherapy, such as vincristine sulfate, carboplatin, cyclophosphamide, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving chemotherapy with radiation therapy may kill more tumor cells and allow doctors to save the part of the body where the cancer started.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ACNS1123 : Phase 2 Trial of Response-Based Radiation Therapy for Patients...
        Protocol No.
        HSC20130346X
        Official Title
        ACNS1123 : Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
        Description
        Drugs used as chemotherapy, such as carboplatin, etoposide, and ifosfamide work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x rays to kill tumor cells. Giving chemotherapy with radiation therapy may kill more tumor cells. This phase II trial studies how well chemotherapy and radiation therapy work in treating younger patients with newly diagnosed central nervous system germ cell tumors.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ACNS1221, A Phase II Study For The Treatment Of Non-Metastatic Nodular...
        Protocol No.
        HSC20160159XT
        Official Title
        ACNS1221, A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years Of Age
        Description
        1.1 Primary Aims Estimate of the PFS distribution for patients 0-
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ALTE07C1 Neuropsychological, Social, Emotional, and Behavioral Outcomes in...
        Protocol No.
        HSC20090042X
        Official Title
        ALTE07C1 Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
        Description
        This research trial studies neuropsychological (learning, remembering or thinking) and behavioral testing in younger patients with cancer. Collecting information over time from a series of tests may help doctors develop effective tests to measure neuropsychological and behavioral function of patients with cancer. Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery testing at 9, 30, and 60 months post-diagnosis in a 1-hour session conducted by a neuropsychologist or psychologist. The Battery consists of tests of intelligence, processing speed/attention, memory, language preference, general developmental progress, attention and behavior/social/emotional function, executive function, adoptive function, and quality of life. Additionally, parents complete a parent-report questionnaire to gather information about patient''s function in terms of attention, memory, executive abilities, and behavioral, social, and emotional adaption.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   An Open-Label Non-Randomized, Multi-Center Phase-2 Study of...
        Protocol No.
        HSC20160689HU
        Official Title
        An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Glioblastoma at First Recurrence or Progression (CTMS# 16-0088)
        Description
        Primary To determine the objective response rate (ORR) per iRANO criteria following intra- and peritumoral infusion using CED of MDNA55 in adult subjects with GB at first recurrence following standard therapy Secondary To assess the safety of MDNA55 following CED in adult subjects with GB at first recurrence following standard therapy. To assess overall survival (OS) in these subjects To assess progression-free survival (PFS; using iRANO criteria) in these subjects Exploratory To assess the pharmacokinetics (PK) of MDNA55 in peripheral plasma as measured by enzyme-linked immunosorbent assay (ELISA) To assess anti-MDNA55 antibody titer and, if anti-MDNA55 titer is observed, determine neutralizing antibody titer and its effect on the safety and efficacy of MDNA55 To perform additional ad hoc efficacy and safety analyses as needed based on the data acquired in this study
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   COG ANBLOOB1: Neuroblastoma Biology Studies
        Protocol No.
        HSC20010176X
        Official Title
        COG ANBLOOB1: Neuroblastoma Biology Studies
        Description
        This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early...
        Protocol No.
        HSC20170313HU
        Official Title
        EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma (CTMS# 17-0041)
        Description
        Primary Aims To determine whether binary changes (increase vs. decrease) in normalized rCBV within enhancing tumor from baseline to 2 weeks after initiation of anti-angiogenic therapy is associated with overall survival (OS).
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Proton Beam Radiation Therapy vs. Conventional Beam Radiation Therapy: ...
        Protocol No.
        HSC20140495H
        Official Title
        Proton Beam Radiation Therapy vs. Conventional Beam Radiation Therapy: Toxicities During and After Craniospinal Radiation Therapy in Children
        Description
        The number of survivors of pediatric brain tumors has greatly increased in the past two decades making it apparent that many are left with life- long   physical  and  neurodevelopmental  impairments  secondary  to  life-  saving  treatments  (particularly  radiotherapy)  received  for  their  disease.  An  emerging  radiotherapy  technology  using  protons  (Proton  Beam  Radiation  Therapy;  PBRT)  rather  than  conventional  photons  or  x-  rays  promises  to  reduce  toxicity  burden  and  improve  outcomes  and  quality  of  life  in  survivors.  Many  herald  the  clinical  potential  of  PBRT  to  minimize  damage  to  healthy  brain  tissue  and  other  organs  of  the  body  without  sacrificing  disease  control. Still, there are no published reports to date of neurocognitive outcomes following PBRT for pediatric brain tumor. In this study, we propose to evaluate the full range of side- effects (e.g. fatigue, nausea/vomiting, hearing loss, cognitive skills, behavioral and emotional adjustment) experienced by children undergoing PBRT in the first year after initiation of treatment, and comparing these to the side effects experienced by children receiving conventional radiation therapy (CRT). We will also compare the financial costs associated with the two types of radiotherapy. This line of research will guide clinicians on the range of outcomes that can be expected following PBRT and stands to influence clinical care in four contexts: 1) decision making, 2) cost, 3) access, and 4) intervention.  
        Contact
        210-450-5924
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   SCUSF0901 [ACCL0922] A Phase II Placebo-Controlled Trial of Modafinil to...
        Protocol No.
        HSC20130255X
        Official Title
        SCUSF0901 [ACCL0922] A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor
        Description
        RATIONALE: Modafinil may help improve memory, attention, and fatigue caused by cancer treatment. PURPOSE: This phase II randomized trial studies how well modafinil works in treating children with memory and attention problems caused by cancer treatment for a brain tumor.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Breast

      •   A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3...
        Protocol No.
        HSC20150602HU
        Official Title
        A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects (CTMS# 15-2100)
        Description
        Primary Objectives Assess the impact of dietary (omega 3 FFA) or pharmacological (ASA) COX-2 inhibitors on: patient serum-induced expression of PGE2 and aromatase by neoplastic mammary epithelial cells circulating levels of pro-inflammatory cytokines (i.e. IL-6, TNF-¿, IGF-1), steroids (i.e. estrogen and testosterone) and lipids (omega-6 and omega-3 PUFAs) Secondary Objectives Correlation for body mass index impact on response to COX2 inhibition.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3...
        Protocol No.
        HSC20160665HU
        Official Title
        A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3 Free Fatty Acid Supplementation on Breast Cancer (CTMS# 16-0119)
        Description
        Primary Objectives Assess the impact of dietary omega 3 FFA: Serum CSF-1 levels patient serum-induced expression of PGE2 by neoplastic mammary epithelial cells, OM3/OM6 circulating levels of pro-inflammatory cytokines (i.e. IL-6, TNF-¿, IGF-1), steroids (i.e. estrogen and testosterone) and lipids (omega-6 and omega-3 PUFAs) Secondary Objectives Tissue expression of aromatase, CSF1/CSF1R and infiltrating macrophage number and polarity.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 2 Study of Poziotinib in Patients with HER2-Positive Metastatic...
        Protocol No.
        HSC20160122HU
        Official Title
        A Phase 2 Study of Poziotinib in Patients with HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC (CTMS# 16-0003)
        Description
        Primary Objective To evaluate the Objective Response Rate (ORR) of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) Secondary Objectives To assess the safety and tolerability of poziotinib in patients with HER2-positive MBC To evaluate other efficacy variables of poziotinib in patients with HER2-positive MBC, including the following: Progression-Free Survival (PFS) Disease Control Rate (DCR) Overall Survival (OS) Time to Progression (TTP)
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study...
        Protocol No.
        HSC20170263HU
        Official Title
        A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Ribociclib with Endocrine Therapy As An Adjuvant Treatment In Patients with Hormone Receptor-Positive, HER2-Negative, High Risk Early Breast Cancer (CTMS# 17-0054)
        Description
        Primary: To compare iDFS for ribociclib + ET versus placebo + ET in patients with HR-positive, HER2-negative, high-risk EBC. Secondary: To evaluate the two treatment groups with respect to recurrence-free survival (RFS) To evaluate the two treatment groups with respect to distant disease-free survival (DDFS) To evaluate the two treatment groups with respect to overall survival (OS) To evaluate patients reported outcomes for health-related quality of life in the two treatment groups To evaluate safety and tolerability of the treatment regimen
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A PILOT STUDY OF HYDROXYTYROSOL, A COMPONENT OF OLIVE OIL FOR BREAST CANCER...
        Protocol No.
        HSC20160660HU
        Official Title
        A PILOT STUDY OF HYDROXYTYROSOL, A COMPONENT OF OLIVE OIL FOR BREAST CANCER PREVENTION IN WOMEN AT HIGH RISK OF BREAST CANCER (CTMS# 16-0068)
        Description
        Primary ¿ To conduct a pilot breast cancer prevention study of hydroxytyrosol in women at increased risk of breast cancer. ¿ To assess whether mammographic density is reduced in pre or post menopausal women at high risk of breast cancer taking hydroxytyrosol for 1 year compared with baseline. Secondary ¿ To assess the toxicity of hydroxytyrosol
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Pre-surgical Clinical Trial of Therapy with S-equol in Women with Triple...
        Protocol No.
        HSC20150231H
        Official Title
        A Pre-surgical Clinical Trial of Therapy with S-equol in Women with Triple Negative Breast Cancer (CTMS# 14-2018)
        Description
        After a baseline breast tumor core biopsy, eligible women with triple negative breast cancer (ER- alpha, PR and HER-2 receptor negative) will be treated with S-equol at a dose of 50 mg twice daily for a period of about 14 days (10-21 day range). After completion of treatment, a second breast tumor sample will be obtained to compare molecular changes between the two specimens. The second pathology specimen may be from the surgical resection of the breast tumor, or a repeat core needle biopsy, if no further surgery is planned. The primary endpoint will be the absolute change in the Ki67, which is a validated marker of tumor proliferation in breast cancer. Secondary endpoints will include assessment of total ER-beta and pY36 levels as measured by immunohistochemical staining and their correlation with S-equol effects. Further treatment after surgical resection or second core needle biopsy of the tumor will be guided by tumor size, nodal status and other standard parameters, and is at the discretion of the treating physician. The Investigator hypothesizes that S-equol will cause a measurable decrease in Ki-67 in estrogen receptor beta expressing triple negative breast cancers, indicating its potential efficacy in this tumor type.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A study attempting to improve the comfort during screening mammography...
        Protocol No.
        HSC20160392HU
        Official Title
        A study attempting to improve the comfort during screening mammography (CTMS# 16-0045)
        Description
        To determine in a randomized trial whether it is possible to decrease the discomfort and anxiety of mammography by using the local analgesic lidocaine, or by using calming music in patients receiving a mammogram.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Aging mammary stem cells and breast cancer prevention (CTMS# 15-2096)
        Protocol No.
        HSC20150556HU
        Official Title
        Aging mammary stem cells and breast cancer prevention (CTMS# 15-2096)
        Description
        To examine whether aging increases human mammary stem/progenitor cells (MaSC) with aberrant phenotypes and if rapamycin can reduce malignant markers and MaSC number in surgical specimens.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Alliance A011401 Randomized Phase III Trial Evaluating the Role of Weight...
        Protocol No.
        HSC20160530XT
        Official Title
        Alliance A011401 Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
        Description
        Primary Objective To compare the effect of a supervised weight loss intervention plus health education materials versus health education materials alone upon invasive disease free survival (iDFS) in overweight (BMI 27-29.9 kg/m2) and obese (BMI ¿30kg/m2) women diagnosed with HER-2 negative, stage II and III breast cancer. Secondary Objectives To determine the relationship between changes in weight and iDFS, and to explore interaction between the level of clinical benefit from weight loss and the intervention. To evaluate the effect of a supervised weight loss intervention upon: a) Overall survival b) Distant disease free survival c) Weight d) Body composition (as measured by waist and hip circumference) e) Insulin Resistance Syndrome associated conditions ¿ diabetes, hospitalization for CV disease To determine the impact of a supervised weight loss intervention on IDFS within subgroups of women with 1) hormone receptor positive breast cancer and 2) hormone receptor negative breast cancer. To determine the impact of a supervised weight loss intervention on IDFS within subgroups of 1) premenopausal women and 2) post-menopausal women.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Breast Epithelial Cells from High-Risk Women for Breast Cancer #14-0041
        Protocol No.
        HSC20150001H
        Official Title
        Breast Epithelial Cells from High-Risk Women for Breast Cancer #14-0041
        Description
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With...
        Protocol No.
        HSC20150697HU
        Official Title
        NRG-BR003, A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (CTMS# 15-2089)
        Description
        Primary Objective To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the invasive disease-free survival (IDFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. Secondary Objectives To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the overall survival (OS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the breast cancer-free survival (BCFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the recurrence-free interval (RFI) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the distant recurrence-free interval (DRFI) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. To determine the toxicity of doxorubicin/cyclophosphamide followed by paclitaxel administered concurrently with carboplatin compared to the toxicity of doxorubicin/cyclophosphamide followed by paclitaxel alone. To determine if germline BRCA status is associated with benefit in IDFS or OS from the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel in patients with operable node-positive or high-risk node-negative triple-negative breast cancer. To determine if the addition of carboplatin will improve the RFI among the homologous recombination (HR) deficient patients as determined by the homologous recombination deficiency (HRD) score. To determine whether the efficacy of carboplatin on RFI in HR-deficient patients differs from that in patients who are not HR-deficient. To collect tissue and blood samples at several occasions for future biomarkers development in predicting risk of breast cancer recurrence in patients with operable node-positive or high-risk node-negative triple-negative breast cancer treated with doxorubicin/cyclophosphamide followed by paclitaxel with or without carboplatin and predicting benefit from the addition of carboplatin among these patients.
        Contact
        410-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Factors influencing decision on prophylactic surgery in Hispanic high risk...
        Protocol No.
        HSC20170066HU
        Official Title
        Factors influencing decision on prophylactic surgery in Hispanic high risk breast cancer patients of South Texas and their health care providers (CTMS# 16-0095)
        Description
        Identify the factors that play a role in decision-making regarding RRPM in Hispanic women of GRACIAS Texas compared with non-Hispanic whites Assess the patient/provider communication regarding RRPM in South Texas Determine if differences in understanding and barriers to RRPM differ between Hispanic and Non-Hispanic white women.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   NSABP B-51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy...
        Protocol No.
        HSC20150021X
        Official Title
        NSABP B-51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant ChemotherapyWho Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
        Description
        To evaluate whether the addition of chest wall + regional nodal radiation therapy (XRT) after mastectomy or breast + regional nodal XRT after breast conserving surgery will significantly reduce the rate of events for invasive breast cancer recurrence-free interval (IBC-RFI) in patients who present with histologically positive axillary nodes but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.
        Contact
        210-450-5924
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs....
        Protocol No.
        HSC20160505HU
        Official Title
        Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (CTMS# 16-0014)
        Description
        Primary Objective ¿ To assess the effect of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on bi-compartmental [both central nervous system (CNS) and non-CNS] progression-free survival (PFS) based on independent central review Secondary Objectives ¿ To assess the effect of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on bi-compartmental PFS based on investigator assessment ¿ To assess the effect of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on PFS, separately in the CNS and non-CNS compartments ¿ To assess the effects of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on time to CNS progression ¿ To assess the effects of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on objective response rate (ORR), separately in the CNS and non-CNS compartments ¿ To assess the duration of response of ONT-380 in combination with capecitabine and trastuzumab, separately in the CNS and non-CNS compartments ¿ To assess the clinical benefit rate (CBR) [stable disease (SD) for ¿ 6 months, or best response of complete response (CR) or partial response (PR)] of ONT-380 vs. placebo in combination with capecitabine and trastuzumab, separately in the CNS and non-CNS compartments ¿ To assess the effects of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on overall survival (OS) ¿ To assess the safety and tolerability of ONT-380 in combination with capecitabine and trastuzumab
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   S1207 - Hormone Therapy With or Without Everolimus in Treating Patients with...
        Protocol No.
        HSC20140060X
        Official Title
        S1207, Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (CTRC# 13-0002)
        Description
        The purpose of this study is to determine whether adding a year of everolimus to standard adjuvant hormonal therapy improves disease-free interval in patients with hormone-receptor-positive and HER2-negative breast cancer. Eligible adult patients (either sex) have a diagnosis of breast cancer and have completed surgery, radiation therapy, and/or adjuvant or neoadjuvant chemotherapy and have no evidence of disease at time of study entry. Patients with inflammatory breast cancer or metastatic disease, serious cardiac disease, uncontrolled diabetes, hepatitis, uncontrolled pulmonary disease, or impaired gastrointestinal function are not eligible. Estimated Enrollment: 3500 patients from multiple cancer centers in the US.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab...
        Protocol No.
        HSC20150769HU
        Official Title
        A Phase Ib, Open-Label, Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (anti-PD-L1 Antibody) in Combination with Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Patients with HER2-Positive Breast Cancer and Atezolizumb with Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer (CTMS# 15-2125)
        Description
        Efficacy Objectives The primary efficacy objective for this study is to evaluate the safety and tolerability of the following combination treatments administered q3w to patients with HER2-positive MBC or operable LABC or inflammatory EBC: ¿ Atezolizumab in combination with trastuzumab and pertuzumab ¿ Atezolizumab in combination with trastuzumab emtansine Pharmacokinetic Objectives The pharmacokinetic (PK) objectives for this study are as follows: ¿ To characterize the pharmacokinetics of atezolizumab, trastuzumab, and pertuzumab when administered concurrently in treatment-naive patients with both metastatic and operable LABC or inflammatory EBC ¿ To characterize the pharmacokinetics of atezolizumab and trastuzumab emtansine when administered concurrently in treatment-naive patients with both metastatic and operable LABC or inflammatory EBC Exploratory Clinical Activity Objectives The exploratory clinical activity objectives of this study for patients in the safety-evaluation cohorts are as follows: ¿ To assess the clinical activity of atezolizumab when administered with either trastuzumab and pertuzumab or trastuzumab emtansine in patients with MBC, as measured by PFS, ORR, and duration of objective response (DOR) among patients with an OR per investigator assessment using RECIST v1.1 ¿ To assess the clinical activity of atezolizumab when administered with either trastuzumab and pertuzumab or trastuzumab emtansine in patients with MBC, as measured by PFS, ORR, and DOR per immune-modified RECIST To assess the clinical activity of atezolizumab when administered with either trastuzumab and pertuzumab or trastuzumab emtansine in patients with operable LABC or inflammatory EBC as measured by the rate of pathologic complete response (pCR; i.e., ypT0/Tis ypN0 in the current AJCC staging system) at breast surgery following completion of neoadjuvant systemic therapy. Exploratory Biomarker Objectives The exploratory objectives for this study are as follows: ¿ To identify candidate biomarkers that correlate with safety signals ¿ To assess changes in expression levels of biomarker or biomarker panels during and after investigational treatment with atezolizumab, trastuzumab, and pertuzumab, and atezolizumab plus trastuzumab emtansine
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Colon

      •   A pilot study to evaluate the chemopreventive effects of epigallocatechin...
        Protocol No.
        HSC20160446HU
        Official Title
        A pilot study to evaluate the chemopreventive effects of epigallocatechin gallate (EGCG) in colorectal cancer (CRC) patients with curative resections (CTMS# 16-0085)
        Description
        To evaluate the preventive effects of EGCG on colonic tissue in patients with resected colorectal cancer when compared to patients on observation.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Modulation of Autophagy: A Clinical Study of Vorinostat plus...
        Protocol No.
        HSC20150178HU
        Official Title
        Modulation of Autophagy: A Clinical Study of Vorinostat plus Hydroxychloroquine versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)
        Description
        To determine the clinical efficacy with progression-free survival (PFS-1) of the combination of VOR plus HCQ when compared to RGF in treatment-refractory mCRC.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon...
        Protocol No.
        HSC20160555HU
        Official Title
        Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon Cancer and Treat Colitis (CTMS#16-0101)
        Description
        This study will evaluate the expression of B7-H1 in human colon tissue, define B7-H1 signaling pathways in colon cells and test the ability of recombinant Listeria to modulate B7-H1 in human colonic tissues in vitro.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   SWOG S0820, Adenoma and Second Primary Colorectal Cancer Prevention Trial...
        Protocol No.
        HSC20130412H
        Official Title
        S0820 - A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) (CTRC#13-0036)
        Description
        The study is designed to investigate whether eflornithine, sulindac or both are effective in preventing or delaying adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer. The primary objective is to assess whether eflornithine and/or sulindac are effective in reducing the recurrence rate at 3 years. The study will enroll approximately 1340 participants from hundreds of cancer centers in the US. In addition to other conditions for enrollment, eligible patients have a history of stage 0-III colon cancer that was surgically removed up to 1 year previously; rectosigmoid cancers are eligible if no prior radiation therapy, no evidence of cancer by colonoscopy exam at time of study entry, and able to take oral medications. Patients who have a history of uncontrolled hypertension or gastric/duodenal ulcer within past year or other medical conditions may not be eligible to enroll.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Esophagus

      •   A Five Part, Phase 1, Multi-center, Open-label Study of DKN-01 in...
        Protocol No.
        HSC20140189H
        Official Title
        A Five Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part C: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal or Gastro-esophageal Junction Adenocarcinoma; Part D: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Squamous Cell Cancer; Part E: An Expansion Cohort in Patients with Relapsed or Refractory Gastric Adenocarcinoma with Wnt Signaling Alterations (CTRC# 14-0002)
        Description
        A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel in participants with refractory/recurrent esophageal or gastro-esophageal junction cancer Part A is a Dose-Escalation Study in Participants with Relapsed or Refractory Esophageal Cancer or Gastro-Esophageal Junction Tumors. Part B is an Expansion Cohort in Participants with Relapsed or Refractory Esophageal Cancer or Gastro-Esophageal Junction Tumors
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Acetic Acid Chromoendoscopy in Barrett''s esophagus surveillance is superior...
        Protocol No.
        HSC20160676HU
        Official Title
        Acetic Acid Chromoendoscopy in Barrett''s esophagus surveillance is superior to the standardized random biopsy protocol in detecting neoplasia: A Prosepective Randomized Trial
        Description
        To compare neoplasia yield when using acetic acid chromoendoscopy in versus the neoplasia yield from standardized random biopsy protocol in Barretts esophagus surveillance population at DHR
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Hodgkin's Lymphoma

      •   A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability,...
        Protocol No.
        HSC20150395HU
        Official Title
        A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma (CTRC# 15-2052
        Description
        Primary objectives: Evaluate the safety and tolerability and determine the maximum tolerated dose (MTD) of ADCT-301 in patients with relapsed/refractory lymphoma Determine the recommended dose of ADCT-301 for Part 2 (expansion). Secondary objectives: Evaluate the activity of ADCT-301 measured by overall response rate, duration of response, progression-free survival, and overall survival. Characterize the pharmacokinetic (PK) profile of HuMax-TAC (total antibody; drug-to-antibody ratio [DAR] ¿0), PBD-conjugated HuMax-TAC (DAR ¿1), and free warhead SG3199. Evaluate anti-drug antibodies (ADAs) in blood before, during, and after treatment with ADCT-301. Exploratory objectives: Evaluate the pharmacodynamic (PD) profile of ADCT-301 as measured by correlation between clinical activity and CD25 expression level in tumor tissue, soluble CD25, and DNA cross-links in blood. Evaluate the PK and PD relationship of ADCT-301. Evaluate the change in white blood cell populations (such as activated T -cells) before, during, and after treatment with ADCT-301 (Part 2 only). Explore the ADCT-301 and free warhead SG3199 concentration-QTc interval relationship.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND...
        Protocol No.
        HSC20150884XT
        Official Title
        AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
        Description
        Primary Aims 1.1.1 To assess the event free survival (EFS) of a novel regimen incorporating brentuximab vedotin (Bv; AdcetrisTM) in the chemotherapy backbone of doxorubicin (Adriamycin), vincristine, etoposide, prednisone and cyclophosphamide (Bv-AVEPC) in newly diagnosed high-risk cHL compared to those treated with ABVE-PC. Secondary Aims 1.2.1 To determine whether children/adolescents with high-risk cHL treated with Bv-AVEPC have a higher rate of early response (determined by FDG-PET) and a reduction in response-directed radiation therapy (RT) compared to those treated with ABVE-PC. 1.2.2 To compare the rate of neuropathy (> Grade 3) among patients treated on the Bv-AVEPC (experimental arm) to patients treated on the ABVE-PC (standard arm). Exploratory Aims Childhood International Prognostic Score (CHIPS) 1.3.1 To validate and compare the Childhood Hodgkin International Prognostic Score (CHIPS) to conventional Ann Arbor Stage (Stages II B with bulk, III B, IV A or B) in predicting outcome in high-risk childhood cHL. Biology 1.3.2 To determine the incidence of preferentially expressed antigen in melanoma (PRAME) and testis-specific antigens in EBV- cHL tumors and the incidence of EBV antigens (EBNA1, LMP1, LMP2) in EBV+ cHL tumors, with the goal of developing strategies to integrate cellular therapy into treatment for newly diagnosed high-risk cHL. Imaging 1.3.3 To incorporate qualitative visual FDG-PET into response-directed treatment algorithms and explore quantitative FDG-PET and CT definitions of tumor burden and response for incorporation into next generation pediatric cHL risk-stratification schemes. Radiation Therapy 1.3.4 To evaluate the reduction in normal tissue irradiation associated with the current treatment approach compared to the volume of historic IFRT fields. 1.3.5 To evaluate EFS and patterns of relapse following protocol-specified RT utilization and treatment volumes. Patient Reported Outcomes (PRO) of Peripheral Neuropathy and Health-Related Quality of Life 1.3.6 To characterize the extent of chemotherapy induced peripheral neuropathy (CIPN), as reported by patients and parent proxies, through serial administration of the FACT-GOG-NTX. 1.3.7 To describe the Health-Related Quality of Life (HRQL) consequences of peripheral neuropathy over time by correlating total neuropathy scale scores with the individual items with the CHRIs-Global scale (e.g., physical health, pain, emotional functioning). 1.3.8 To perform a cross validation of the FACT-GOG-NTX with the TNS-PV to determine the performance of both measures with the use of brentuximab vedotin in a limited institutional approach in children and adolescents with cHL (See Appendix VII). Economic (For US Institutions Only) 1.3.9 To assess the resource use and cost implications of Bv in combination with chemotherapy and radiotherapy (RT) for newly diagnosed high-risk cHL in children and adolescents (See Appendix VIII).
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma A...
        Protocol No.
        HSC20140059X
        Official Title
        Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma A Groupwide Non-Therapeutic Protocol
        Description
        This clinical trial studies blood sample markers of reproductive hormones in assessing ovarian reserve in younger patients with newly diagnosed lymphomas. Studying samples of blood from patients with cancer in the laboratory may help measure the effect of curative therapy for lymphoma on ovarian failure.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Kidney

      •   AREN03B2 Renal Tumors Classification, Biology and Banking Study
        Protocol No.
        HSC20070394X
        Official Title
        AREN03B2 Renal Tumors Classification, Biology and Banking Study
        Description
        This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   EA8143, A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs....
        Protocol No.
        HSC20170129HU
        Official Title
        EA8143, A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) (CTMS# 16-0148)
        Description
        Primary Objectives To compare recurrence-free survival (RFS) between patients with locally advanced renal cell carcinoma randomly assigned to perioperative nivolumab in conjunction with radical or partial nephrectomy with patients randomized to surgery alone. Secondary Objectives To evaluate for differences in recurrence-free survival associated with perioperative nivolumab compared to surgery alone among the subset of patients with clear cell histology. To compare the overall survival between patients randomized to perioperative nivolumab in addition to resection to patients randomized to primary tumor resection alone. To describe the safety and tolerability of perioperative nivolumab
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Viral Reporters to Determine Circulating Tumor Cells Level and Viability in...
        Protocol No.
        HSC20140294H
        Official Title
        Viral Reporters to Determine Circulating Tumor Cells Level and Viability in Patients with Kidney Cancer: A Pilot Study
        Description
        Primary objective: Determine if our novel ex-vivo diagnostic assays, Circulating Tumor Cells Reporter Vector (CTC-RV) is capable of detecting a reporter signal from the collected blood and urine samples of patients with kidney cancer.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Leukemia, other

      •   COG AALL05B1, A Children''s Oncology Group Protocol for Collecting and...
        Protocol No.
        HSC20070100X
        Official Title
        COG AALL05B1, A Children''s Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
        Description
        RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors learn more about cancer and help predict the recurrence of cancer. PURPOSE: This research study is collecting and storing samples of bone marrow and blood from patients with relapsed acute lymphoblastic leukemia or relapsed non-Hodgkin lymphoma.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Liver

      •   AHEP0731 Treatment of Children with all Stages of Hepatoblastoma
        Protocol No.
        HSC20100158X
        Official Title
        AHEP0731 Treatment of Children with all Stages of Hepatoblastoma
        Description
        This phase III trial studies the side effects and how well risk-based therapy works in treating younger patients with newly diagnosed liver cancer. Surgery, chemotherapy drugs (cancer fighting medicines), and when necessary liver transplant are the main current treatments for hepatoblastoma. The stage of the cancer is one factor used to decide the best treatment. Treating patients according to the risk group they are in may help get rid of the cancer, keep it from coming back, and decrease the side effects of chemotherapy.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Hepatocellular Carcinoma Tissue Acquisition
        Protocol No.
        HSC20150834HU
        Official Title
        Hepatocellular Carcinoma Tissue Acquisition
        Description
        Obtain biopsy specimens from Hispanic patients with liver cancer when they come to Radiology clinic for ablation therapy
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Modulation of Sorafenib induced autophagy using hydroxychloroquine in...
        Protocol No.
        HSC20160515HU
        Official Title
        Modulation of Sorafenib induced autophagy using hydroxychloroquine in hepatocellular cancer (CTMS# 16-0076)
        Description
        Primary Objective(s): To determine the clinical efficacy with to determine the clinical efficacy with time to tumor progression (TTP) of the combination of HCQ and sorafenib in first line advanced HCC (cohort 1); and the addition of HCQ to sorafenib in patients who progress on sorafenib (cohort 2). Secondary Objective(s): To determine the overall survival in advanced HCC patients receiving HCQ and sorafenib in both cohort 1 and 2 To evaluate the tumor response rate in advanced HCC patients receiving HCQ and sorafenib To further define the safety in advanced HCC patients receiving HCQ and sorafenib To identify biomarkers of autophagy modulation and immune markers that correlate with clinical efficacy in advanced HCC patients receiving HCQ and sorafenib.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to...
        Protocol No.
        HSC20150732HU
        Official Title
        A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Carcinoma Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder (CTMS# 15-2112)
        Description
        The primary objective of this study is: ¿ To characterize the safety and tolerability of DKN-01 in combination with gemcitabine and cisplatin in patients with carcinoma primary to the intra- or extra-hepatic biliary system or gallbladder. The secondary objectives of this study are: ¿ To estimate the overall response rate (ORR), progression free survival (PFS), duration of response (DoR), and overall survival (OS)of patients with carcinoma primary to the intra- or extra-hepatic biliary system or gallbladder treated with DKN-01 in combination with gemcitabine and cisplatin. ¿ To characterize the pharmacokinetics of DKN-01 in combination with gemcitabine and cisplatin in patients with carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Lung

      •   Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With Advanced...
        Protocol No.
        HSC20150625HU
        Official Title
        A Phase II, Multicenter, Three-Cohort Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-Type (wt), Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease (CTMS# 15-2074)
        Description
        Primary objective: To demonstrate the antitumor activity of INC280, as measured by overall response rate (ORR) by Blinded Independent Review Committee (BIRC) assessment, by cohort Key secondary objective: To evaluate duration of response (DOR) as assessed by BIRC, by cohort Secondary Objectives Objective 1: To evaluate ORR and DOR by investigator assessment, by cohort Objective 2: To evaluate time to response (TTR), disease control rate (DCR) and progression-free survival (PFS) by investigator and by BIRC assessment, by cohort Objective 3: To evaluate overall survival (OS), by cohort Objective 4: To evaluate INC280 safety profile as monotherapy in NSCLC patients who have received one or two prior lines of systemic therapy in advanced/metastatic setting Objective 5: To characterize the pharmacokinetics of INC280
        Contact
        410-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy...
        Protocol No.
        HSC20150302XT
        Official Title
        S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Screening Step) Lung-MAP Sub-Study (CTRC #14-0036)
        Description
        The overarching goal for this protocol is to establish a National Clinical Trials Network (NCTN) mechanism for genomically screening large but homogeneous cancer populations and subsequently assigning and accruing simultaneously to a multi-sub­ study Master Protocol. Biomarker-driven sub-studies in this protocol will compare new targeted therapy (TT) or targeted therapy combinations (TTC) to standard of care (SoC) therapy based on designated therapeutic biomarker-drug combinations, with the ultimate goal being approval of new targeted therapies in this setting. In addition, the protocol includes a non-match sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy (NMT) to SoC also with the goal of approval. We hypothesize that this Master Protocol mechanism will yield definable and measurable efficiencies in terms of improving genomic screening of cancer patients for clinical trial entry, and improved time lines for drug-biomarker testing allowing for inclusion of the maximum numbers of otherwise eligible patients in comparison with currently employed single screen-single trial approaches.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   S1403, A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus...
        Protocol No.
        HSC20150454XT
        Official Title
        S1403, A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (CTMS #15-2060)
        Description
        Objective: The purpose of this study is to compare the effects, good and/or bad, of using afatinib along with cetuximab to using afatinib alone in participants with non-small cell lung cancer which has an EGFR positive genetic mutation. The addition of cetuximab to the usual afatinib could shrink the cancer, but it could also cause side effects. The study will be considered positive if the study approach increases life by eight months or more compared to the usual approach.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Lymphoid Leukemia

      •   AALL08B1, Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
        Protocol No.
        HSC20110017X
        Official Title
        AALL08B1, Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
        Description
        This research trial studies a risk-based classification system for patients with newly diagnosed acute lymphoblastic leukemia. Gathering health information about patients with acute lymphoblastic leukemia may help doctors learn more about the disease and plan the best treatment.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk...
        Protocol No.
        HSC20110028X
        Official Title
        AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)
        Description
        This partially randomized phase III clinical trial is studying different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk...
        Protocol No.
        HSC20120250X
        Official Title
        AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
        Description
        This randomized phase III trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed high-risk acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AALL1231 - A Phase III Randomized Trial Investigating Bortezomib (NSC#...
        Protocol No.
        HSC20150314X
        Official Title
        AALL1231 - A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL)and T- Lymphoblastic Lymphoma (T-LLy)A Groupwide Phase III Study
        Description
        Primary Aims: To compare EFS in patients with newly diagnosed T-ALL and T-LLy who are randomized to a modified ABFM backbone versus bortezomib plus the modified ABFM backbone. Secondary Aims: 1)To determine the safety and feasibility of modifying standard therapy for T-ALL and T-LLy based on the results of UKALL 2003, which includes a dexamethasone-based Induction, additional doses of pegaspargase (PEG-ASP) during Induction and Delayed Intensification (DI), and dexamethasone pulses during Maintenance therapy 2)To determine if prophylactic (presymptomatic) cranial radiation therapy (CRT) can be safely and effectively eliminated in the 85-90% of T-ALL patients classified as standard or intermediate risk. 3)To determine the proportion of EOC MRD ¿ 0.1% T-ALL patients who become MRD negative (undetectable by flow cytometry) after intensification of chemotherapy, using three high risk (HR) BFM blocks, and to compare EFS between the patients who become MRD negative after the three HR BFM blocks and continue on chemotherapy with those who continue to have detectable MRD and are eligible for other treatment strategies, including hematopoietic stem cell transplant (HSCT). Similarly, to compare the EFS between very high risk (Induction failure) T-LLy patients treated with HR BFM intensification blocks who have partial or complete response (PR or CR) with those who do not respond (NR). Correlative Aims: 1)To investigate the prognostic significance of Day 29 BM MRD in T-LLy patients. 2)To determine if protein expression patterns can predict bortezomib response and drug resistance in T-ALL 3)To analyze and target relevant signaling pathways in T-ALL blasts, focusing on Early T cell Precursor (ETP) ALL
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ACCL1033, A Comprehensive Approach to Improve Medication Adherence in...
        Protocol No.
        HSC20130254X
        Official Title
        ACCL1033, A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
        Description
        This randomized phase III trial studies compliance to a mercaptopurine treatment intervention compared to standard of care in younger patients with acute lymphoblastic leukemia in remission. Assessing ways to help patients who have acute lymphoblastic leukemia to take their medications as prescribed may help them in taking their medications more consistently and may improve treatment outcomes.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ACCL1333/CV185155A, Phase III Randomized, Open Label, Multi-center Study of...
        Protocol No.
        HSC20150889HU
        Official Title
        ACCL1333/CV185155A, Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-Asparaginase
        Description
        Primary Objectives: 1)To compare the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on the composite endpoint of adjudicated non-fatal deep vein thrombosis (DVT, including symptomatic and asymptomatic), pulmonary embolism (PE), and cerebral venous sinus thrombosis (CVST); and venous thromboembolism (VTE)-related-death during 25-28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning central venous access device (CVAD) and receiving PEG L-asparaginase during chemotherapy induction. 2)To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on adjudicated major bleeding events during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. Secondary Objectives: 1) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on single adjudicated endpoints of non-fatal DVT (including symptomatic and asymptomatic), PE, and CVST; and VTE-related-death during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. 2) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on the composite endpoint of adjudicated major and clinically relevant non-major bleeding (CRNMB) events during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed acute ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. Other Objectives: 1) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on single adjudicated endpoints of all cause death; arterial thromboembolic events including paradoxical embolism and stroke and CVAD-related infection events during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. 2) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on single adjudicated endpoints of CRNMB and minor bleeding events during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. 3) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on single endpoints of number of catheter replacements needed during the study; events of CVAD dysfunction with improvement after thrombolytic therapy; and number of platelet transfusions during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. 4) To assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy for ALL or lymphoma (T or B cell), using a population pharmacokinetic (PPK) approach. 5) To characterize the relationship between apixaban plasma concentration and anti-FXa activity in pedi
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   INCB 18424-269 (COG AALL1521), A Phase 2 Study of the JAK1/JAK2 Inhibitor...
        Protocol No.
        HSC20160625HU
        Official Title
        INCB 18424-269 (COG AALL1521), A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2 Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
        Description
        Primary Objectives: Part 1 - To evaluate initial safety and tolerability and to define the recommended Part 2 dose (RP2D) of ruxolitinib in combination with multi-agent chemotherapy in children and adolescents or young adults (AYA) with de novo high-risk (HR) Philadelphia chromosome¿like (Ph-like) cytokine receptor¿like factor 2 rearranged (CRLF2-R) and/or Janus kinase (JAK) pathway¿mutant B-cell acute lymphoblastic leukemia (B-ALL). Part 2 - To determine the efficacy of ruxolitinib in combination with chemotherapy for children and AYA with de novo HR Ph-like CRLF2-R and/or JAK pathway¿mutant B-ALL. Secondary Objective: - To characterize the safety and potential toxicity of ruxolitinib combined with chemotherapy throughout the course of treatment in children and AYA with de novo HR Ph-like CRLF2-R and/or JAK pathway¿mutant B-ALL. Exploratory Objectives: - To assess the pharmacokinetics (PK) of ruxolitinib in combination with chemotherapy in children and AYA with B-ALL. - To assess rates of minimal residual disease (MRD) at end-Consolidation in end-Induction MRD+ subjects who are treated with ruxolitinib and chemotherapy. - To measure pharmacodynamic (PD) signaling inhibition and biomarkers of ruxolitinib activity, for correlation with ruxolitinib PK and with efficacy measures. - To evaluate the overall survival (OS) of all subjects receiving ruxolitinib in combination with chemotherapy.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Multiple Myeloma

      •   An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab,...
        Protocol No.
        HSC20160389HU
        Official Title
        An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma (CheckMate 602: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 602) (CTMS# 16-0039)
        Description
        Primary Objectives: The co-primary objectives are to compare the following between N-Pd and Pd arms: The objective response rate (ORR) by IRC The progression free survival (PFS) by IRC Secondary Objectives To assess the time to objective response (TTR) within N-Pd and Pd arms To assess the duration of objective response (DOR) within N-Pd and Pd arms To assess ORR and PFS by Investigator within N-Pd and Pd arms Exploratory Objectives To estimate overall survival of each of the 3 treatment groups To evaluate efficacy of NE-Pd in subjects with relapsed and/or refractory multiple Myeloma within NE-Pd arm through the assessment of ORR and PFS To evaluate efficacy of NE-Pd in subjects cross-over from the control arm (Pd) to the exploratory arm (NE-Pd) through the assessment of ORR and PFS To assess safety and tolerability To characterize the pharmacokinetics of nivolumab and elotuzumab when administered in combination with elotuzumab, pomalidomide and dexamethasone To characterize the immunogenicity of nivolumab and elotuzumab when administered in combination with elotuzumab, pomalidomide and dexamethasone To assess patient-reported outcomes in disease-related symptoms using MDASI-MM, EORTC QLQ-C30 and EQ-5D
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Bortezomib or Carfilzomib with Lenalidomide & Dexamethasone in patients with...
        Protocol No.
        HSC20150407XT
        Official Title
        E1A11, Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) (CTMS 15-2043)
        Description
        Primary Objective To compare the overall survival between two strategies of lenalidomide maintenance following induction with a proteasome inhibitor¿IMiD combination: limited duration of maintenance (24 months) versus indefinite maintenance therapy until disease progression. Secondary Objectives To compare the progression-free survival between two strategies of lenalidomide maintenance following induction with a proteasome inhibitor¿IMiD combination: limited duration of maintenance (24 months) or indefinite maintenance therapy until disease progression. To compare the progression-free survival between VRd and CRd induction followed by lenalidomide maintenance in patients with newly diagnosed symptomatic multiple myeloma. To compare induction rates of response between VRd and CRd arms. To evaluate the time to progression, duration of response and overall survival between VRd and CRd induction therapy. To compare induction rates of toxicity between VRd and CRd arms. To evaluate toxicity during lenalidomide maintenance. Quality of Life Objectives To compare the short and long-term health-related quality of life impact between two strategies of lenalidomide maintenance following induction with a proteasome inhibitor¿IMiD combination: limited duration of maintenance (24 months) versus indefinite maintenance therapy until disease progression. To compare the impact on health-related quality of life between VRd and CRd induction therapy. To evaluate the association between early induction response and change in health-related quality of life. To describe changes in health-related quality of life during the induction, active maintenance and observation phases. To evaluate correlation between treatment adherence during maintenance and health-related quality of life. Correlative Laboratory Study Objectives To compare induction minimal residual disease negativity rates between VRd and CRd arms. To compare minimal residual disease negativity rates between two strategies of lenalidomide maintenance following induction with a proteasome inhibitor¿IMiD combination: limited duration of maintenance (24 months) versus indefinite maintenance therapy until disease progression. To describe changes in minimal residual disease during the induction and active maintenance phases and explore association with response.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with...
        Protocol No.
        HSC20150751HU
        Official Title
        MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer) (CTMS# 15-2082)
        Description
        Primary Objective To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas. Secondary Objectives To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas. To evaluate time until death or disease progression. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, RNA and protein-based assessment platforms.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   MATCH Treatment Subprotocol R: EAY131-R: Phase II Study of Trametinib in...
        Protocol No.
        HSC20170217HU
        Official Title
        MATCH Treatment Subprotocol R: EAY131-R: Phase II Study of Trametinib in Patients with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations (CTMS# 15-2084)
        Description
        Primary Objective To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas. Secondary Objectives To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas. To evaluate time until death or disease progression. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, RNA and protein-based assessment platforms.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Myeloid and Monocytic Leukemia

      •   AAML1031, A Phase III Randomized Trial for Patients with de novo AML using...
        Protocol No.
        HSC20130256X
        Official Title
        AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
        Description
        This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib and sorafenib tosylate together with combination chemotherapy may be an effective treatment for acute myeloid leukemia.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Non-Hodgkin's Lymphoma

      •   A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or...
        Protocol No.
        HSC20160299XT
        Official Title
        A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117
        Description
        1.1 Primary Aims 1.1.1 Tolerability - To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (ALCL99) and to determine the tolerability of crizotinib given in combination with chemotherapy (ALCL99). 1.1.2 Event Free Survival -To estimate the Event Free Survival (EFS) of Arm BV and Arm CZ and contrast these to historical control data. 1.2 Secondary Aim 1.2.1 MDD/MRD - To determine the prognostic significance of minimal disseminated disease (MDD) at diagnosis and minimal residual disease (MRD) as measured by RT- polymerase chain reaction (PCR) in peripheral blood.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Other Endocrine System

    •   Other Hematopoietic

      •   AAML08B1 Biology Study of Transient Myeloproliferative Disorder (TMD) in...
        Protocol No.
        HSC20110348X
        Official Title
        AAML08B1 Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)
        Description
        RATIONALE: Studying the genes expressed in samples of blood from patients with Down syndrome may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at blood samples from newborns with Down syndrome.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Ovary

      •   Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in...
        Protocol No.
        HSC20160447HU
        Official Title
        Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer (CTMS# 16-0046)
        Description
        Primary objectives: ¿ Phase 1: To evaluate dose-limiting toxicities (DLTs) of combination treatment with niraparib and pembrolizumab during the first cycle of treatment, and to establish a recommended Phase 2 dose (RP2D) and schedule ¿ Phase 2: To estimate the clinical activity of combination treatment with niraparib and pembrolizumab in terms of objective response rate (ORR) as assessed by the Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 separately for the triple-negative breast cancer (TNBC) and ovarian cancer (OC) cohorts. Secondary objectives: ¿ Phase 1 and Phase 2: To evaluate the safety and tolerability of combination treatment with niraparib and pembrolizumab using Common Terminology Criteria for Adverse Events (CTCAE, v.4.03) ¿ Phase 2: To evaluate additional measures of clinical benefit as assessed by the Investigators, including: ¿ ORR by immune-related RECIST (irRECIST) ¿ Duration of response (DOR) by RECIST v1.1 and irRECIST; ¿ Disease control rate (DCR) by RECIST v1.1 and irRECIST; ¿ Progression-free survival (PFS) by RECIST v1.1 and by irRECIST; ¿ Overall survival (OS). ¿ Phase 1 and 2: To evaluate the pharmacokinetics (PK) of niraparib during combination treatment.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low...
        Protocol No.
        HSC20170396HU
        Official Title
        Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women (CTMS# 17-0014)
        Description
        To evaluate the longitudinal CA-125 algorithm for the early detection of ovarian cancer in a low risk cohort of women.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Pancreas

      •   S1505, A Randomized Phase II Study of Perioperative mFolfirinox Versus...
        Protocol No.
        HSC20160013HU
        Official Title
        S1505, A Randomized Phase II Study of Perioperative mFolfirinox Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma (CTMS# 15-2140)
        Description
        Primary Objectives a. To assess 2-year overall survival in each treatment arm (mFOLFIRINOX and gemcitabine/nab-paclitaxel) in patients with resectable pancreatic cancer. b. If the stated threshold is met in one or both arms: to choose the better regimen with respect to 2-year overall survival. Secondary Objectives To estimate, for all patients and within treatment arms: a. Frequency and severity of adverse events associated with chemotherapy in the perioperative setting. b. Proportion of patients going to surgery for resection after preoperative chemotherapy. c. Proportion of patients achieving R0 resection after preoperative chemotherapy. d. Overall response rate following preoperative chemotherapy, including confirmed and unconfirmed, complete and partial response, per RECIST 1.1. e. Pathologic response rates after R0 or R1 resection. f. Patterns of recurrence (loco-regional, distant) after R0 or R1 resection. g. Disease-free survival from the time of R0 or R1 resection.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Prostate

      •   A Two-Part Prospective Study to Measure the Impact of Adding Genomic Testing...
        Protocol No.
        HSC20160493HU
        Official Title
        A Two-Part Prospective Study to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients with Long Term Follow-up Post-Treatment to Measure the Prediction of Progression/Recurrence in Men Treated in the Veterans Administration Medical Center (VAMC) P-PROVE - Prospective Prolaris® Value and Efficacy
        Description
        The objectives of the study include: ¿ To estimate the impact of a biopsy based genomic risk assessment tool (Prolaris®) on the magnitude of change between the PRE-Prolaris® test selection of treatment option for clinically localized prostate cancer and the ACTUAL implemented treatment administered following the genomic test results. ¿ To estimate the impact of a biopsy based genomic risk assessment tool (Prolaris®) on the magnitude of change between the PRE-Prolaris® test selection of treatment option for early stage prostate cancer and the POSTProlaris ® test treatment plan following consultation with the patient. ¿ To estimate the impact of a biopsy based genomic risk assessment tool (Prolaris®) on the magnitude of change between physician¿s initial likelihood of recommending non-interventional therapy for early stage prostate cancer and the likelihood following the genomic test results
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   An Interventional Study to Reduce Folate Levels in Men on Active...
        Protocol No.
        HSC20160340HU
        Official Title
        An Interventional Study to Reduce Folate Levels in Men on Active Surveillance for Prostate Cancer
        Description
        Ascertain the impact of a low folate (folic acid) enriched diet- a reverse dietary intervention- on prostate cancer prevention and progression.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Banking of Tissue and Establishing Continuous Cell Lines and Xenografts from...
        Protocol No.
        HSC20130429H
        Official Title
        Banking of Tissue and Establishing Continuous Cell Lines and Xenografts from Neoplasia (CTRC#13-0048)
        Description
        Texas Tech Repository
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Biomarkers and clinical parameters associated with Gleason score upgrading
        Protocol No.
        HSC20140367H
        Official Title
        Biomarkers and clinical parameters associated with Gleason score upgrading
        Description
        This study involves the collection of blood samples by finger stick, heel stick, ear stick, or venipuncture from unhealthy adults, pregnant adults or children.  Considering the person’s age, weight, and health, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected the blood samples intended for this study are minimal risk.
        Contact
        210-567-0178
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Clinical Evaluation of the ExoDx Prostate (IntelliScore) in men presenting...
        Protocol No.
        HSC20170067HU
        Official Title
        Clinical Evaluation of the ExoDx Prostate (IntelliScore) in men presenting for initial biopsy: impact on decision-making and health economics
        Description
        1.1. Primary Objective 1.1.1. Evaluate impact of the ExoIntelliScore Prostate on the decision to perform an initial prostate biopsy for men presenting with an elevated PSA (2-10 ng/mL). 1.2. Secondary and Exploratory Objectives 1.2.1. Assess physician satisfaction with the ExoIntelliScore Prostate report including test result presentation, graphics and interpretation. 1.2.2. Assess patient satisfaction for ease of understanding test results and role on decision process to have a biopsy. 1.2.3. Determine the medical economic impact of the ExoIntelliScore Prostate in the prostate biopsy decision process. 1.2.4. Correlation of the ExoIntelliScore Prostate score with the actual biopsy result. 1.2.5. The goal of this study is to evaluate how the urologist will utilize the ExoIntelliScore Prostate score in the decision process to perform an initial prostate needle biopsy for men presenting for an equivocal PSA.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Cognitive impairment associated with androgen deprivation therapy (ADT)...
        Protocol No.
        HSC20160519HU
        Official Title
        Cognitive impairment associated with androgen deprivation therapy (ADT) (CTMS# 16-0103)
        Description
        To assess the effects of androgen-deprivation therapy on cognition among aging men with prostate cancer
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Dynamic Multi-Cohort Prediction Modeling of Prostate Biopsy Outcome
        Protocol No.
        HSC20150050H
        Official Title
        Dynamic Multi-Cohort Prediction Modeling of Prostate Biopsy Outcome
        Description
        Dynamic Multi-Cohort Prediction Modeling of Prostate Biopsy Outcome
        Contact
        210-450-0754
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Hormonal Therapy plus Radiation Therapy as Treatment for Prostate Cancer
        Protocol No.
        HSC20130062H
        Official Title
        RTOG 0924 Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
        Description
        The purpose of this study is determine which type of anti-hormonal therapy and radiation therapy will result in an improvement in survival in patients with “unfavorable” intermediate risk or “favorable” high risk prostate cancer.  The risk is the possibility or chances of the prostate cancer coming back after being treated. The primary objective is to see which treatment improves the duration of survival. The study will enroll 2,580 participants from many cancer centers in the US. In addition to other conditions for enrollment, men who were diagnosed with prostate cancer within the past 180 days and have no evidence of lymph node involvement by CT scan or MRI within the past 90 days may be enrolled. Men are not eligible for this study if the prostate or testes have been surgically removed. Men who have already been treated with brachytherapy or radiation to the pelvis or hormonal therapy are not enrolled. Patients with a history of other cancers may not be eligible.
        Contact
        210-450-5924
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Identification of Protein and Genetic Biomarkers of Prostate Cancer and Risk...
        Protocol No.
        HSC20020380H
        Official Title
        Identification of Protein and Genetic Biomarkers of Prostate Cancer and Risk Factors for Progression of Disease
        Description
        The purpose of this study is to identify genetic variants that predict progression of prostate cancer.
        Contact
        210-567-0178
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Impact of a home-based exercise program on prognostic biomarkers in men with...
        Protocol No.
        HSC20160604HU
        Official Title
        Impact of a home-based exercise program on prognostic biomarkers in men with prostate cancer (CTMS 15-0008)
        Description
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Impact of Yoga as Complementary Therapy on Quality of Live, Pro-Inflammatory...
        Protocol No.
        HSC20150406H
        Official Title
        Impact of Yoga as Complementary Therapy on Quality of Live, Pro-Inflammatory and Cellular Immune Biomarkers in Patients Undergoing Radical Prostatectomy: A Pilot Randomized Controlled Trial
        Description
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Prostate MRI as a Screening Tool to Detect Prostate Cancer (Novel Prostate...
        Protocol No.
        HSC20150160H
        Official Title
        Prostate MRI as a Screening Tool to Detect Prostate Cancer (Novel Prostate MRI Technique as a Prostate Cancer Biomarker)
        Description
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Prostate Wash Epithelial Cell Repository (PWER) (CTRC#12-0070)
        Protocol No.
        HSC20120262H
        Official Title
        Prostate Wash Epithelial Cell Repository (PWER) (CTRC#12-0070)
        Description
        This tissue bank will store epithelial cell samples from prostate biopsies and measure Prostate Specific Antigen (PSA) and Prostate Specific Membrane Antigen (PSMA) in the urine specimens for future scientific research studies.  The stored specimens will be used for research investigating the causes of prostate diseases, the methods for improving diagnosis, and highly aggressive forms from less aggressive forms of prostate cancers.
        Contact
        210-450-0754
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR)
        Protocol No.
        HSC20000030H
        Official Title
        San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR)
        Description
        The San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR), is a long-term research study of a large group of men that will help researchers improve the detection of prostate cancer.  The program provides annual PSA (Prostate Specific Antigen) screening at no cost.  Subjects participating in this study will be asked to attend one visit per year for PSA screening and complete annual follow-up phone interviews. Written PSA results will be provided to you, and if you request, to your provider
        Contact
        210-567-0178
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Texas Cancer Diagnostics Pipeline Consortium, Lab on a Chip
        Protocol No.
        HSC20110483H
        Official Title
        Texas Cancer Diagnostics Pipeline Consortium, Lab on a Chip
        Description
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Tissue Bank and Data Base for Urologic Diseases
        Protocol No.
        HSC20050234H
        Official Title
        Tissue Bank and Data Base for Urologic Diseases
        Description
        The purpose of this project is to establish a high-quality repository of male and female genitourinary tissue specimens with an associated database of relevant clinical, follow-up and outcome data.  Development and maintenance of a high-quality repository is essential to the conduct of translational research for genitourinary cancer. When possible, specimens will be accrued by freezing fresh excess tissue removed at surgery or biopsy. No extra tissue will be removed during surgery expressly for the repository. Specimens will also be obtained from archival paraffin-embedded tissue. Clinical data will be obtained from tumor registry files, from subjects, or review of medical records.
        Contact
        210-567-0178
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Soft Tissue

      •   A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
        Protocol No.
        HSC19990345X
        Official Title
        A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
        Description
        The purpose of this study is to collect and store tumor tissue, blood, and bone marrow samples from patients with soft tissue sarcoma that will be tested in the laboratory. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients to test in the laboratory may help the study of cancer.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide...
        Protocol No.
        HSC20160538XT
        Official Title
        A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
        Description
        Primary Aims: 1.1 To compare the event-free survival (EFS) of patients with IR RMS treated with surgery, radiotherapy, and VAC alternating with VI (VAC/VI) to that of patients treated with surgery, radiotherapy and VAC/VI plus temsirolimus (TORI). Secondary Aims: 1.2 To compare the overall survival (OS) of patients with IR RMS treated with surgery, radiotherapy, and VAC alternating with VI to that of patients treated with surgery, radiotherapy and VAC/VI plus TORI. Exploratory Aims: 1.3.1 To compare the outcome of patients based on their FOXO1 fusion gene partner, by evaluation PAX3 vs. PAX7 in all patients found to be FOXO1 fusion positive. 1.3.2 To compare the outcome of patients based on their [F18]-fluorodeoxy-D-glucose-positron emission tomography (FDG-PET) response at Week 9 (positive or negative), as assessed by Deauville Criteria (5-point).
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ARST1321 - Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue...
        Protocol No.
        HSC20150224X
        Official Title
        ARST1321 - Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
        Description
        ARST1321
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Thyroid

    •   Urinary Bladder

      •   A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability,...
        Protocol No.
        HSC20170102HU
        Official Title
        A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oradoxel Monotherapy in Subjects with Advanced Malignancies (CTMS# 16-0069)
        Description
        Primary Objective: To determine the maximum tolerated dose (MTD) of Oradoxel based on dose-limiting toxicity (DLT) in subjects with advanced malignancies Secondary Objectives To determine the safety and tolerability of docetaxel as Oradoxel To determine the incidence of unacceptable toxicity with Oradoxel To determine the recommended Phase 2 dose (RP2D) of docetaxel as Oradoxel To characterize the pharmacokinetic (PK) profile of docetaxel as Oradoxel To evaluate tumor response
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability,...
        Protocol No.
        HSC20160087HU
        Official Title
        A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oraxol in Subjects with Advanced Malignancies (CTMS# 15-2137)
        Description
        Primary Objective To determine the maximum tolerated dose (MTD) and dosing regimen of Oraxol in subjects with advanced malignancies Secondary Objectives To determine the recommended Phase 2 dose of paclitaxel as Oraxol To determine the safety and tolerability of paclitaxel as Oraxol To characterize the pharmacokinetic (PK) profile of paclitaxel as Oraxol To evaluate the tumor response
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an...
        Protocol No.
        HSC20170110HU
        Official Title
        A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors (CTMS# 16-0091)
        Description
        Primary Objectives: Part 1 ¿ Dose Escalation Cohorts: ¿ To evaluate the safety and tolerability of TSR-042 using Common Terminology Criteria for Adverse Events (CTCAE v.4.03) in patients with advanced solid tumors Part 2 ¿ Expansion Cohorts: ¿ To evaluate the antitumor activity of TSR-042 in patients with advanced solid tumors, in terms of objective response rate (ORR) as assessed by the Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Part 1 and Part 2: ¿ To define the recommended Phase 2 dose (RP2D) and schedule Secondary Objectives: Part 1 ¿ Dose Escalation Cohorts: ¿ To characterize the pharmacodynamic (PDy) profile of TSR-042 ¿ To evaluate ORR as assessed by the Investigators using RECIST v1.1 Part 2 ¿ Expansion Cohorts: ¿ To characterize the safety and tolerability of TSR-042 using CTCAE v.4.03 Part 1 and Part 2: ¿ To characterize the pharmacokinetic (PK) profile of TSR-042 ¿ To evaluate the immunogenicity of TSR-042 ¿ To evaluate additional measures of clinical benefit, including: ¿ ORR by immune-related RECIST (irRECIST) ¿ Duration of response (DOR) by RECIST v 1.1 ¿ Disease control rate (DCR) by RECIST v 1.1 and by irRECIST ¿ Progression-free survival (PFS) by RECIST v 1.1 and by irRECIST ¿ Overall survival (OS)
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 1 Study of CBL0137 in Patients with Metastatic or Unresectable...
        Protocol No.
        HSC20130328H
        Official Title
        A Phase 1 Trial of CBL0137 In patients With Metastatic or Unresectable Advanced Solid Neoplasms or Refractory Lymphomas (CTRC# 13-0031)
        Description
        This Phase 1 study is designed to determine the best dose of CBL0137 to use when treating patients with metastatic or unresectable advanced solid tumors or lymphoma. The study will enroll up to 48 patients from at least 2 cancer centers in the US. In addition to other conditions for enrollment, eligible patients have cancer that has not improved or has come back after prior treatment and are otherwise in good health. Patients who have a history of active infection, cancer involving the central nervous system, a particular EKG abnormality or other serious medical conditions may not be eligible to enroll.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 1/2A, Multicenter, Open-Label Study of LYC-55716 in Adult Subjects...
        Protocol No.
        HSC20160617HU
        Official Title
        A Phase 1/2A, Multicenter, Open-Label Study of LYC-55716 in Adult Subjects with Locally Advanced or Metastatic Cancer (CTMS# 16-0099)
        Description
        Primary Objectives Phase 1 Evaluate the safety and tolerability of LYC-55716 Determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) Phase 2a Determine the objective response rate according to response evaluation criteria in solid tumors (RECIST) v1.1 Secondary Objectives Phase 1 Evaluate the activity of LYC-55716 by objective response according to RECIST v1.1 Determine the durability of any observed objective response Phase 2a Determine the duration of response Determine progression-free survival (PFS) and overall survival (OS) Determine suitability of the RP2D for further study Characterize the pharmacokinetics (PK) of LYC-55716 Exploratory Objectives Assess tumor activity in subjects with locally advanced or metastatic cancer according to immune-related response evaluation criteria in solid tumors (irRECIST) Exploratory analysis of metabolite in plasma Assess changes in circulating tumor markers (eg, cytokines/chemokines)
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 1b Study of Oraxol in Combination with Ramucirumab in Patients with...
        Protocol No.
        HSC20170188HU
        Official Title
        A Phase 1b Study of Oraxol in Combination with Ramucirumab in Patients with Gastric, Gastro-esophageal, or Esophageal Cancers (CTMS# 16-0089)
        Description
        Primary Objective: To determine the maximum tolerated dose (MTD) of Oraxol in patients with advanced stage gastric, gastro-esophageal, or esophageal cancers who are being treated with Oraxol in combination with ramucirumab Secondary Objectives: To determine the safety and tolerability of Oraxol in combination with ramucirumab To determine the recommended Phase 2 dose of Oraxol in combination with ramucirumab To characterize the pharmacokinetic (PK) profile of Oraxol in combination with ramucirumab To characterize preliminary activity of Oraxol plus ramucirumab as determined by response rate, progression-free survival, and overall survival
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a...
        Protocol No.
        HSC20170071HU
        Official Title
        A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors (CTMS# 16-0084)
        Description
        Primary objective: To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of ARRY-382 in combination with pembrolizumab in patients with selected solid tumors Secondary objectives: ¿ To describe the preliminary antitumor activity of the combination based on the Response Criteria In Solid Tumors, version 1.1 (RECIST v1.1) ¿ To describe the preliminary antitumor activity of the combination based on immune-related response criteria (irRC) ¿ To characterize the safety and tolerability of the combination, including acute and chronic toxicities ¿ To evaluate the pharmacokinetics of ARRY-382 in combination with pembrolizumab Exploratory objective: ¿ To explore the effect of the combination on circulating biomarkers of immune response ¿ To describe the preliminary antitumor activity of the combination in patients with PD-L1¿positive non¿small cell lung cancer (NSCLC), as determined using a United States Food and Drug Administration (FDA)-approved test, using RECIST ¿ To describe the preliminary antitumor activity of the combination in patients with PD-L1¿positive non¿small cell lung cancer (NSCLC), as determined using an FDA approved test, using irRC
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial...
        Protocol No.
        HSC20170212HU
        Official Title
        A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (CTMS# 17-0021)
        Description
        Phase 1 (Dose Escalation: Metastatic Melanoma) Primary Objectives To assess the safety and tolerability of escalating intratumoral doses of SD-101 in combination with intravenous pembrolizumab in patients with metastatic melanoma To evaluate the expression of IFN-inducible genes in whole blood 24 hours after intratumoral injection of SD-101 given with pembrolizumab in patients with metastatic melanoma as a pharmacodynamic marker of SD-101 activity To determine a RP2D of SD-101 in combination with pembrolizumab to be evaluated in Phase 2 Exploratory Objectives To assess the preliminary response both locally and systemically including: Treatment response of the injected Lesion A (local response) Treatment response of the non-injected lesion(s) (systemic response) Treatment response of all lesions Time to tumor response To assess changes in tumor biomarkers Phase 2 (Dose Expansion: Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma) Primary Objectives To assess the tumor response both locally and systemically including: Treatment response of the injected lesion(s) (local response) Treatment response of the non-injected lesion(s) (systemic response) Treatment response of all lesions Secondary Objectives To assess the safety and tolerability of SD-101 in combination with pembrolizumab To assess the time frame of tumor responses: Time to tumor response Duration of response To assess PFS
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy...
        Protocol No.
        HSC20160220HU
        Official Title
        A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (CTMS# 16-0035)
        Description
        Primary Objective: ¿ To evaluate the antitumor activity of niraparib in patients with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer as assessed by overall response rate (ORR) Secondary Objectives: ¿ To evaluate the durability of the antitumor activity of niraparib ¿ To evaluate antitumor activity of niraparib in homologous recombination deficiency (HRD)-positive patients and in patients with germline breast cancer gene mutation (gBRCAmut) ¿ To evaluate the following additional measures of clinical benefit of niraparib: ¿ Disease control rate (DCR) ¿ Progression-free survival (PFS) ¿ Overall survival (OS) ¿ To evaluate the safety and tolerability of niraparib Exploratory Objectives: ¿ To evaluate QTc in a subset of niraparib-treated ovarian cancer patients ¿ To assess population pharmacokinetics (PK) and estimate PK parameters for niraparib and its major metabolite ¿ To explore potential biomarkers of poly(ADP-ribose) polymerase (PARP) inhibitor sensitivity and tolerability
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase I, First-in-human, Open-label, Dose-escalation, Safety,...
        Protocol No.
        HSC20160554HU
        Official Title
        A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients with Advanced Solid Tumors (CTMS# 16-0092)
        Description
        Primary Objective: ¿ To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-0903 administered daily for the first 21 days every 4 weeks, over a range of doses in patients with advanced solid tumors. Secondary Objectives: ¿ To establish the pharmacokinetics of orally administered TP-0903 ¿ To observe patients for any evidence of antitumor activity of TP-0903 by objective radiographic assessment ¿ To study the pharmacodynamics of TP-0903 therapy by: ¿ assessing biomarkers in tumor tissue ¿ assessing biomarkers in peripheral blood mononuclear cells (PBMCs) and serum ¿ To establish the Recommended Phase 2 Dose (RP2D) for future studies with TP-0903
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase I, Multicenter, Open-Label Dose Escalation and Expansion Study of...
        Protocol No.
        HSC20150289HU
        Official Title
        A Phase I, Multicenter, Open-Label Dose Escalation and Expansion Study of PCA062, Administered Intravenously In Adult Patients With pCAD-Positive Tumors (CTMS# 14-2019)
        Description
        Primary Objective To determine the MTD/RDE of PCA062 in patients with pCAD-positive tumors in the dose escalation part. Secondary Objectives To characterize the safety and tolerability of PCA062 To characterize the pharmacokinetic profile of PCA062 To assess emergence of anti-PCA062 antibodies following one or more intravenous infusions of PCA062 To assess the preliminary anti-tumor activity of PCA062 in patients with pCAD-positive triple negative breast cancer (TBNC), head and neck squamous cell carcinoma (HNSCC) or esophageal cancer (squamous and adenocarcinoma)
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase I/II, open label, multicenter study of the safety and efficacy of...
        Protocol No.
        HSC20150421HU
        Official Title
        A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies (CTMS #15-2054)
        Description
        Primary Objectives Phase I part To estimate the RP2D or MTD for the single agent LAG525 and the combination of LAG525 and PDR001. Phase II part To estimate the overall response rate per RECIST V1.1 for single agent LAG525 as well as for the combination of LAG525 and PDR001 Secondary Objectives: To characterize the safety and tolerability of single agent LAG525 given alone and in combination with PDR001 To characterize the pharmacokinetic profile of single agent LAG525 given alone and in combination with PDR001 To assess emergence of anti-LAG525, and anti-PDR001 antibodies following one or more intravenous (i.v.) infusions of single agent LAG525 given alone or in combination with PDR001 To assess potential predictors of efficacy of single agent LAG525 and the combination of LAG525 and PDR001 To evaluate the preliminary antitumor activity of single agent LAG525 given alone or in combination of PDR001 To investigate patient selection and pharmacodynamic biomarkers in tumor tissue samples
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase I/II, Open-Label, Multi-Center Study of the Safety and Efficacy of...
        Protocol No.
        HSC20160420HU
        Official Title
        A Phase I/II, Open-Label, Multi-Center Study of the Safety and Efficacy of BLZ945 as Single Agent and In Combination with PDR001 in Adult Patients with Advanced Solid Tumors (CTMS# 16-0071)
        Description
        Primary Objective: Phase I: To characterize the safety and tolerability of BLZ945 as a single agent and in combination with PDR001 and to identify the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D). Phase II: To assess the anti-tumor activity of BLZ945 in combination with PDR001 (and as single agent if appropriate) in patients with advanced solid tumors. Secondary Objective: Phase I: To characterize the pharmacodynamics effect of BLZ945 as a single agent and in combination with PDR001. To characterize PK of BLZ945 as a single agent and in combination with PDR001. To assess the preliminary anti-tumor activity of BLZ945 as single agent and in combination with PDR001. Phase I and II: To assess emergence of anti-PDR001 antibodies when BLZ945 is administered in combination with PDR001.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib...
        Protocol No.
        HSC20170106HU
        Official Title
        A Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155) (CTMS# 16-0009)
        Description
        Primary Objective Objective: In both the Dose Evaluation and Signal Detection phases, evaluate the safety and tolerability of the treatment combination. Objective: Within each disease type of the Signal Detection phase, evaluate objective response rate (ORR) according to investigator assessment using the disease specific criteria. Secondary Objective: Objective: To evaluate the Objective Response Rate (ORR; complete response [CR] + partial response [PR]) of the combination of pembrolizumab and dinaciclib within each disease type, ie, CLL based on iwCLL guidelines (Hallek, 2008) [1], MM based on IMWG criteria (Durie, 2006) [2] and DLBCL based on the Revised Response Criteria for Malignant Lymphoma (Cheson, 2007) [3]. Objective: Within each disease type of the Signal Detection phase, evaluate Duration of Response (DOR), Progression-Free Survival (PFS) according to investigator assessment using the disease specific criteria; and Overall Survival (OS).
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase III, Open Label Study to Evaluate the Safety and Efficacy of...
        Protocol No.
        HSC20160351HU
        Official Title
        A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd- IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC)
        Description
        To evaluate the incidence of Event-Free Survival at 12 months, where Event-Free Survival is defined as High-Grade-Recurrence Free Survival
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab...
        Protocol No.
        HSC20150561HU
        Official Title
        A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients with PD-L1-Selected, High-Risk Muscle-Invasive Bladder Cancer After Cystectomy (CTMS# 15-2067)
        Description
        Efficacy Objectives The primary efficacy objective for this study is as follows: ¿ To evaluate the efficacy of adjuvant MPDL3280A treatment in patients with PD- L1¿selected muscle invasive bladder cancer (MIBC), as measured by disease-free survival (DFS) The secondary efficacy objectives for this study are as follows: ¿ To evaluate the efficacy of adjuvant MPDL3280A treatment, as measured by overall survival (OS) ¿ To evaluate the efficacy of adjuvant MPDL3280A treatment, as measured by disease-specific survival (DSS) ¿ To evaluate the efficacy of adjuvant MPDL3280A treatment, as measured by distant metastasis-free survival (DMFS) Safety Objectives The safety objectives for this study are as follows: ¿ To evaluate the safety and tolerability of MPDL3280A in the adjuvant setting ¿ To evaluate the incidence of anti-therapeutic antibodies (ATAs) against MPDL3280A and to explore the potential relationship of the immunogenicity response with pharmacokinetics, safety, and efficacy Pharmacokinetic Objective The pharmacokinetic (PK) objective for this study is as follows: ¿ To characterize the pharmacokinetics of MPDL32820A Patient-Reported Outcome Objective The patient-reported outcome (PRO) objective for this study is as follows: ¿ To assess health status as measured by the EuroQol 5-dimension, 5-level version (EQ-5D-5L) questionnaire Exploratory Objective The exploratory objective for this study is as follows: ¿ To assess predictive, prognostic, and pharmacodynamic exploratory biomarkers in archival and/or fresh tumor tissue and blood and their association with disease recurrence Country-Specific Objectives The primary country-specific objective is to evaluate the efficacy of MPDL3280A adjuvant treatment in patients who are residents of China, with PD-L1-selected MIBC after cystectomy, as measured by DFS. There are no country-specific secondary objectives for the population of Chinese patients. Country¿specific exploratory objectives for the Chinese patient population are identical to the secondary efficacy, safety, PK, and PRO objectives specified above.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Randomized study of rapamycin combined with intravesical BCG in patients...
        Protocol No.
        HSC20160162HU
        Official Title
        A Randomized study of rapamycin combined with intravesical BCG in patients with non-muscle invasive bladder cancer
        Description
        1.1 The primary objectives of the study are to determine: a. The effect of Sirolimus on BCG-specific immunity during treatment of non-muscle invasive bladder cancer with maintenance BCG 1.2 Secondary objectives of the study are to determine: a. The compare the effects of very low-dose versus low-dose Sirolimus on BCG-specific immunity during treatment of non-muscle invasive bladder cancer with maintenance BCG
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ABTR01B1, A Children''s Oncology Group Protocol for Collecting and Banking...
        Protocol No.
        HSC20040131H
        Official Title
        ABTR01B1, A Children''s Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
        Description
        This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ACCL15N1CD Use of Evidence-Based Supportive Care Clinical Practice...
        Protocol No.
        HSC20160673X
        Official Title
        ACCL15N1CD Use of Evidence-Based Supportive Care Clinical Practice Guidelines in Pediatric
        Description
        Primary and Secondary Aims Aim 1: Chart Review To measure the rate of adherence to selected COG-endorsed supportive care CPG recommendations at NCORP sites Aim 1a To describe the possible influence of NCORP site size and the number of patients enrolled in COG studies per site on the delivery of CPG-consistent care. Aim 1b To describe the clinical outcome of episodes during which patients receive CPG-consistent or CPG-inconsistent care Aim 2: Focus Groups To describe facilitators of and barriers to the use of CPGs elicited via focus group interviews with a diverse set of potential users (physician, nurse, nurse practitioner and pharmacists) who provide pediatric cancer care at NCORP sites. Aim 3: Interviews To improve how well CPG recommendations are understood by health care providers by refining the CPG recommendation format based on an iterative process of cognitive interviewing and formatting revisions. Understanding is defined as the correct interpretation of the course of action recommended or suggested by a CPG.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ACCRN07 Protocol for the Enrollment on the Official COG Registry, The...
        Protocol No.
        HSC20080271X
        Official Title
        ACCRN07 Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
        Description
        The Children s Oncology Group has established a research network, the Childhood Cancer Research Network (CCRN), to collect information about children with cancer and other conditions that are benign but involve abnormal cell growth in order to help doctors and scientists better understand childhood cancer. The CCRN''s goal is to collect clinical information about every child diagnosed with cancer and similar conditions in the United States and Canada, to allow researchers to study patterns, characteristics, and causes of childhood cancer. The information can also help researchers study the causes of childhood cancer. To expand the CCRN, parents of children who have been diagnosed with cancer will be asked to provide information about themselves and their child for research purposes.   Objectives: To obtain informed consent from parents (and the child, when appropriate) of infants, children, adolescents, and young adults newly diagnosed with cancer to enter their names and certain information concerning their child into the Childhood Cancer Research Network. To obtain informed consent from parents (and the child, when appropriate) of infants, children, adolescents, and young adults newly diagnosed with cancer for permission to be contacted in the future to consider participating in non-therapeutic and prevention research studies involving the parents and/or the child.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ALTE05N1, Umbrella Long-Term Follow-Up Protocol
        Protocol No.
        HSC20090478X
        Official Title
        ALTE05N1, Umbrella Long-Term Follow-Up Protocol
        Description
        Umbrella Long-Term Follow-Up Protocol
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ALTE1621 Pharmacologic Reversal of Ventricular Remodeling in Childhood...
        Protocol No.
        HSC20160394X
        Official Title
        ALTE1621 Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
        Description
        1.1 Primary Aim To determine the impact of a two-year course of low-dose carvedilol on surrogate echocardiographic indices of heart failure (HF) risk, including: ¿ Left Ventricular (LV) Posterior Wall Thickness-Dimension Ratio (LV T-D) a wellestablished index of early myocardial remodeling and subsequent HF risk (primary endpoint). ¿ LV systolic and diastolic function, and afterload ¿ established echocardiographic indices associated with HF risk. ¿ Natriuretic peptides, troponins, and Galectin-3 - circulating biomarkers associated with myocardial injury, and HF risk. 1.2 Secondary Aims 1.2.1 To establish safety and tolerability of this two-year course of low-dose carvedilol, assessing both objective measures (hepatic function) and patient reported outcomes. 1.2.2 To examine the modifying effect of demographic, clinical, and molecular characteristics on the risk: benefit ratio from this two-year carvedilol intervention. 1.3 Exploratory Aim To evaluate the long-term efficacy of carvedilol in preventing cardiomyopathy and/or heart failure in high-risk childhood cancer survivors.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AN EARLY-PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND...
        Protocol No.
        HSC20150549H
        Official Title
        AN EARLY-PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS
        Description
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   An Open-Label Rollover Study to Evaluate the Long-Term Safety, Tolerability,...
        Protocol No.
        HSC20170197XT
        Official Title
        An Open-Label Rollover Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity of Oral TVB-2640 in Patients With Solid Tumors Previously Enrolled in 3V2640-CLIN-002 (CTMS# 17-0046)
        Description
        Primary: ¿ To continue to characterize the safety profile of TVB-2640. Secondary: ¿ To identify any early signs of anti-tumor activity, where possible.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   An Open-Label, Dose Escalation, Phase 1, First-In-Human Study of TAK-659 in...
        Protocol No.
        HSC20150255HU
        Official Title
        An Open-Label, Dose Escalation, Phase 1, First-In-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumors and Lymphoma Malignancies (CTMS# 14-2013)
        Description
        To determine the safety, tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) ofTAK-659 administered orally on a daily dosing schedule in patients with advanced solid tumor and lymphoma who do not have effective standard treatment available
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   APEC14B1, THE PROJECT: EVERYCHILD PROTOCOL: A REGISTRY, ELIGIBILITY...
        Protocol No.
        HSC20150870XT
        Official Title
        APEC14B1, THE PROJECT: EVERYCHILD PROTOCOL: A REGISTRY, ELIGIBILITY SCREENING, BIOLOGY AND OUTCOME STUDY
        Description
        1.1 To maintain a Childhood Cancer Registry1 for infants, children, adolescents, and young adults with cancer. 1.2 To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto COG therapeutic clinical trials. 1.3 To develop a well annotated childhood cancer biorepository for current and future research through the collection of biospecimens (at diagnosis, time of progression, time of recurrence and/or post-mortem), including tumor, host and when feasible parental germline DNA; and key clinical data, including presentation, diagnostic, staging, summary treatment, and outcome information, from every child diagnosed with cancer at COG institutions. 1.4 To allow use of registry data for permission to be contacted in the future to consider participating in non-therapeutic and prevention research studies involving the child or their parents.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Cancer Therapy and Research Center''s Institute for Drug Development Solid...
        Protocol No.
        HSC20070684H
        Official Title
        Cancer Therapy and Research Center''s Institute for Drug Development Solid Tumors and Hematological Malignancies Biorepository for Biomarker Discovery
        Description
        Samples are collected for the Cancer Therapy and Research Center''s Solid Tumors and Hematological Malignancies Biorepository for Biomarker Discovery
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Caris Molecular Intelligence® and Caris Centers of Excellence for...
        Protocol No.
        HSC20170144HU
        Official Title
        Caris Molecular Intelligence® and Caris Centers of Excellence for Precision Medicine NetworkTM Retrospective Outcomes-Associated Database (CTMS# 16-0145)
        Description
        The objective of this project is the development of the Caris Molecular Intelligence® and Caris Centers of Excellence for Precision Medicine NetworkTM Outcomes Associated Repository, a disease research database (hereinafter referred to as the ¿Database¿) for the purpose of: 1. Effecting change in disease treatment processes by advancing precision medicine and improving care for cancer through acquiring and sharing valuable molecular tumor profiling information and clinical outcomes in a collaborative, secure environment. 2. Performing prospective research studies involving analyses of quality of life studies as well as subject medical records including clinical presentation and outcomes. This eligible cohort includes select subjects having undergone Caris Molecular Intelligence® evaluation for diagnosis and/or treatment management. 3. Evaluate the frequency of specific clinical events in relation to risk factors, diagnosis and treatments provided via the collection of outcomes data through automated data capture systems provided by a third-party data entity and manually-entered data when needed. 4. Provide information access that is vital to research collaborators, including potential researchers from pharmaceutical companies, governmental agencies, academia, healthcare providers, and payors, with catalogued subject outcome data for the use of drug development discoveries, clinically relevant research trials, publications and posters, the implementation of future healthcare policies, characterization of trends in practice patterns and their relation to subject outcomes and the economic impact of differing evaluation, treatment, and management paradigms. 5. Cultivate a repository for assay development and validation of emerging technologies to enhance clinical cancer care.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
        Protocol No.
        HSC20150542HU
        Official Title
        A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors (CTMS# 15-2071)
        Description
        Primary: To assess the antitumor activity of lurbinectedin (PM01183) in terms of overall response rate (ORR), according to the Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1, in the following advanced solid tumors: small cell lung cancer (SCLC), head and neck carcinoma (H&N), neuroendocrine tumors (NETs), biliary tract carcinoma, endometrial carcinoma, BRCA 1/2-associated metastatic breast carcinoma, carcinoma of unknown primary site, germ cell tumors (GCTs), and Ewing¿s family of tumors (EFTs). Secondary: To further characterize the antitumor activity of PM01183 in terms of duration of response (DR), clinical benefit [ORR or stable disease (SD) lasting over four months (SD ¿ 4 months)], progression-free survival (PFS), and oneyear overall survival (1y-OS) in each cohort of advanced solid tumors. Characterize the plasma pharmacokinetics (PK) of PM01183. To conduct an exploratory pharmacogenomic (PGx) and pharmacogenetic analysis. To evaluate the safety profile of PM01183 in this patient population.
        Contact
        410-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Clinical trial to study the safety and efficacy of MBG453 given alone and in...
        Protocol No.
        HSC20150730HU
        Official Title
        A Phase I-Ib/II, Open-Label, Multi-Center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination with PDR001 in Adult Patients with Advanced Malignancies (CTMS# 15-2114)
        Description
        Primary Objectives: Phase I-Ib: To characterize the safety and tolerability of MBG453 as a single agent and in combination with PDR001 and to identify recommended doses for future studies. Phase I-Ib dose ranging: To further investigate the safety and tolerability of different doses of MBG453 alone or in combination with PDR001. Phase II: To estimate the anti-tumor activity of MBG453 alone in patients with solid tumors, and in combination with PDR001 in selected disease indications (melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC)). Secondary Objectives Evaluate the preliminary anti-tumor activity of MBG453 alone and in combination with PDR001. Make an initial comparison of safety, PK and efficacy for MBG453 and PDR001 administered in combination on a every 2 weeks (Q2W) and every 4 weeks (Q4W) dosing schedules. Characterize the pharmacokinetic profile of MBG453 alone and in combination with PDR001. Assess emergence of anti-MBG453 and anti-PDR001 antibodies. Assess potential predictors of efficacy of MBG453 single agent and in combination with PDR001 in tumor samples. Assess the pharmacodynamic effect of MBG453 as single agent and in combination with PDR001 in tumor samples. Describe the survival distribution of patients treated with MBG453 as single agent and in combination with PDR001 for each disease group.
        Contact
        410-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   DCP-001, Use of a Clinical Trial Screening Tool to Address Cancer Health...
        Protocol No.
        HSC20160342XT
        Official Title
        DCP-001, Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
        Description
        Objectives 1) Implement a screening tool in NCORP to collect broader demographic and clinical data to generate hypothesis and research questions in the following areas of research: cancer screening, cancer prevention, symptom science, cancer care disparities, comparative effectiveness and cancer care delivery research. 2) Collect expanded demographic and clinical data (e.g., SES, co-morbidities, method of diagnosis) across the NCORP network to help identify and best characterize patients that are screened but not enrolled and for patients that participate in NCI trials, to understand how these variables may impact outcomes. 3) Enhance an understanding of site- specific and trial-specific accrual barriers that will inform the development of effective strategies to improve accrual, particularly for minority and underserved populations. 4) Provide data for internal and external evaluation of NCORP¿s first RFA cycle and reissuance.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Evaluating responses to intravesical BCG administration to patients with...
        Protocol No.
        HSC20140002H
        Official Title
        Evaluating responses to intravesical BCG administration to patients with invasive bladder cancer: Defining mechanisms of mTOR inhibition to boost immunotherapy in bladder cancer and Improving immunotherapy in bladder cancer by targeting immune dysfunction
        Description
        Patients with muscle invasive (≥T1) bladder cancer will be given 3-6 treatments (based on treatment response) intravesically TICE® BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis. After completion of BCG treatments the patient will undergo a cystectomy. A portion of bladder tumor tissue and lymph nodes will be collected for research purposes during the cystectomy.
        Contact
        210-450-0507
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   GO29665, A PHASE I/II, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE...
        Protocol No.
        HSC20160080H
        Official Title
        GO29665, A PHASE I/II, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF COBIMETINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS
        Description
        CTRC#15-0005
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Head and Neck Cancer Repository
        Protocol No.
        HSC20170218HR
        Official Title
        Head and Neck Cancer Repository
        Description
        To establish a repository of head and neck cancers and PDX models from our south Texas patient population.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Health Effects after Anthracycline and Radiation Therapy (HEART):...
        Protocol No.
        HSC20140058X
        Official Title
        Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy A Limited Institution Non-Therapeutic Study
        Description
        This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
        Protocol No.
        HSC20080462H
        Official Title
        Inhibition of Autophagy in Solid Tumors: A Phase I Pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in Combination with the HDAC Inhibitor SAHA for the Treatment of Patients with Advanced Solid Tumors with an expansion study in advanced Renal and Colorectal Cancer (CTRC# 08-52)
        Description
        This trial will study hydroxychloroquine (HCQ) and Vorinostat in patients with advanced solid tumors to determine the maximum tolerated dose (MTD) and to evaluate the safety and antitumor activity of this drug combination.  The study is listed on clinicaltrials.gov, NCT01023737. 
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Incidence and Factors Associated with the Development and Severity of Oral...
        Protocol No.
        HSC20050218H
        Official Title
        Incidence and Factors Associated with the Development and Severity of Oral Mucositis in Patients Undergoing High Dose Chemotherapy and Peripheral Stem Cell Transplantation
        Description
        Our study intends to evaluate prospectively the incidence and severity of oral mucositis in patients undergoing high-dose chemotherapy and hematopoietic stem cell transplantation, as well as to evaluate the potential influence of nutritional-, physical-, and transplant-related factors associated with the development of this complication and its grade of involvement. Research plan: This is a prospective cohort study with an observational basis that involves all of the patients undergoing high-dose chemotherapy and peripheral blood stem cell transplantation at the Audie L. Murphy VA Hospital Bone Marrow Transplant Unit and at the University Hospital Bone Marrow Transplant Unit. We expect to enroll 400 patients during a 5-year period. Methods: In order to answer the study questions, subjects will be assessed several times during the study period. The study involves a multidisciplinary group that will be evaluating and following the subjects. A baseline will be established by a physician and a nutritionist before the subjects start the high-dose chemotherapy regimen. The subjects will be followed with oral evaluations 3 times per week, beginning on the day of the transplant and ending when mucositis resolves, or the patient is discharged home, or 30 days post-transplant, whichever occurs first. At day 15 post-transplant, patients will be evaluated for the second time by the nutritionist. Further information such as blood values, use of medications and treatment complications, will be obtained by daily chart review.  
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with...
        Protocol No.
        HSC20150831HU
        Official Title
        MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations (CTMS# 15-2107)
        Description
        Primary Objective To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas. Secondary Objectives To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas. To evaluate time until death or disease progression. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, RNA and protein-based assessment platforms.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   MATCH Treatment Subprotocol C1: EAY131-C1: Crizotinib in Patients with...
        Protocol No.
        HSC20160463HU
        Official Title
        MATCH Treatment Subprotocol C1: EAY131-C1: Crizotinib in Patients with Tumors with MET Amplification (CTMS# 16-0064)
        Description
        The purpose of this study is to test any good and bad effects of the study drug called crizotinib in patients whose cancer has MET genetic changes.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (other...
        Protocol No.
        HSC20150750HU
        Official Title
        MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations (CTMS# 15-2081)
        Description
        Primary Objective To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas. Secondary Objectives To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas. To evaluate time until death or disease progression. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, RNA and protein-based assessment platforms.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   MATCH Treatment Subprotocol S1: Phase II Study of Trametinib in Patients...
        Protocol No.
        HSC20160260HU
        Official Title
        MATCH Treatment Subprotocol S1: Phase II Study of Trametinib in Patients with Tumors with NF1 Mutations (CTMS# 16-0028)
        Description
        PRIMARY OBJECTIVES: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas. SECONDARY OBJECTIVES: I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas. II. To evaluate time until death or disease progression. III. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, ribonucleic acid (RNA) and protein-based assessment platforms.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   MATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors...
        Protocol No.
        HSC20150839HU
        Official Title
        MATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss (CTMS# 15-2110)
        Description
        Primary Objective To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas. Secondary Objectives To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas. To evaluate time until death or disease progression. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, RNA and protein-based assessment platforms.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   MATCH Treatment Subprotocol W: EAY131-W: Phase II Study of AZD4547 in...
        Protocol No.
        HSC20160541HU
        Official Title
        MATCH Treatment Subprotocol W: EAY131-W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway (CTMS# 16-0065)
        Description
        The purpose of this study is to test any good and bad effects of the study drug, AZD4547, in patients whose cancer has genetic changes called FGFR gene alterations.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with...
        Protocol No.
        HSC20160282HU
        Official Title
        MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations (CTMS# 16-0032)
        Description
        PRIMARY OBJECTIVES: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas. SECONDARY OBJECTIVES: I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas. II. To evaluate time until death or disease progression. III. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, ribonucleic acid (RNA) and protein-based assessment platforms.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   MATCH Treatment Subprotocol Z1A: EAY131-Z1A: Binimetinib in Patients with...
        Protocol No.
        HSC20160499HU
        Official Title
        MATCH Treatment Subprotocol Z1A: EAY131-Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations (CTMS# 16-0066)
        Description
        The purpose of this study is to test any good and bad effects of the experimental study drug binimetinib in patients whose cancer has NRAS mutations.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   MATCH Treatment Subprotocol Z1B: EAY131-Z1B: Phase II Study of Palbociclib...
        Protocol No.
        HSC20160491HU
        Official Title
        MATCH Treatment Subprotocol Z1B: EAY131-Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC (CTMS# 16-0067)
        Description
        The purpose of this study is to test any good and bad effects of the study drug, palbociclib, in patients whose cancer has CCND1, 2 or 3 amplification and tested positive for a protein called Rb protein.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Molecular Analysis for Therapy Choice (MATCH) / MATCH Treatment Subprotocol...
        Protocol No.
        HSC20170176HU
        Official Title
        Molecular Analysis for Therapy Choice (MATCH) / MATCH Treatment Subprotocol H: EAY131-H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma, Thyroid Cancer, and Colorectal Adenocarcinoma) (CTMS# 15-2083)
        Description
        Primary Objective To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas. Secondary Objectives To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas. To evaluate time until death or disease progression. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, RNA and protein-based assessment platforms.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Molecular Analysis for Therapy Choice (NCI-MATCH)
        Protocol No.
        HSC20150719HU
        Official Title
        EAY131, Molecular Analysis for Therapy Choice (MATCH) (CTMS# 15-2080)
        Description
        Primary Objective To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas. Secondary Objectives To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas. To evaluate time until death or disease progression. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, RNA and protein-based assessment platforms.
        Contact
        410-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Multi-Institutional Study to Evaluate DNA Methylation Markers for Detection...
        Protocol No.
        HSC20160419HU
        Official Title
        Multi-Institutional Study to Evaluate DNA Methylation Markers for Detection of Primary Bladder Cancers in Urine Samples From a Cohort of Patients With Hematuria
        Description
        The primary objective of this study is to evaluate the performance of the methylation marker panel for the detection of bladder cancer in patients with gross or microscopic hematuria. The secondary objective is to evaluate the predictive accuracy of a risk model including clinical factors such as age, gender, smoking history, and presence of gross versus microscopic hematuria compared to a model incorporating the same risk factors along with the methylation marker panel.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   NRG-HN003, A PHASE I AND EXPANSION COHORT STUDY OF ADJUVANT CISPLATIN,...
        Protocol No.
        HSC20170206HU
        Official Title
        NRG-HN003, A PHASE I AND EXPANSION COHORT STUDY OF ADJUVANT CISPLATIN, INTENSITY-MODULATED RADIOTHERAPY, AND MK-3475 (PEMBROLIZUMAB) IN HIGH-RISK HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) (CTMS# 17-0022)
        Description
        Primary Outcome Measures: DLT in patients with high-risk head and neck squamous cell carcinoma treated with adjuvant cisplatin, IMRT, and pembrolizumab [ Time Frame: Up to 4 weeks post IMRT ] Will be summarized using proportions for binary outcome per cohort.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Phase I Clinical Trial of Camptothecin-20-O-Propionate hydrate (CZ48) (CTMS#...
        Protocol No.
        HSC20150748HU
        Official Title
        Phase I Clinical Trial of Camptothecin-20-O-Propionate hydrate (CZ48) (CTMS# 15-2103)
        Description
        PRIMARY: To describe the dose limiting toxicities and adverse event profile of Camptothecin-20-O-Propionate hydrate (CZ48) administered orally every day. To determine Phase II recommended dose of Camptothecin-20-O-Propionate hydrate (CZ48) administered orally every day. SECONDARY: To perform a pharmacokinetic study of orally administered CZ48. To assess responses by RECIST criteria when applicable. To follow patients for survival.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Phase I study of carfilzomib in combination with cyclophosphamide and...
        Protocol No.
        HSC20160206HU
        Official Title
        Phase I study of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
        Description
        Primary Objective: To determine the DLTs and MTD of carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors Secondary Objectives: 1. To evaluate toxicities of carfilzomib in the pediatric population when combined with conventional chemotherapy 2. To gather preliminary efficacy data on the drug combination 3. To measure if circulating plasma proteasome (cProt) levels post treatment correlate with response to therapy and overall survival 4. To measure if the levels of proteasome activity and resistance to carfilzomib correlates with toxicity and/or response to treatment. 5. To measure if inhibition of proteasome activity by carfilzomib results in alteration in a number of autophagy and apoptosis related proteins, providing means to evaluate correlates of activity of carfilzomib. 6. To measure the level of proteasome inhibition in patient PBMCs before and during treatment by determination of the level of protein ubiquitination. 7. To determine in vitro sensitivity of patient leukemias and solid tumors to carfilzomib alone and in combination with study chemotherapeutic agents in order to generate a predictive model of drug sensitivity. 8. To expand patient leukemia and solid tumor samples in order to save tissue for future studies but also to serve as a pre-clinical in vivo model to be included in the generation and testing of a drug sensitivity predictive model. 9. To perform whole exome sequencing (WES) and RNA seq on patient leukemia and solid tumor samples and WES on germ line DNA in order to determine potential mechanisms of drug sensitivity or resistance as well as contribute to testing a computer `learning engine¿ (Bionet) for predicting clinical responses from genomic and drug sensitivity data.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Phase Ib, open-label, multi-center study to characterize the safety,...
        Protocol No.
        HSC20160552HU
        Official Title
        Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589) (CTMS# 16-0058)
        Description
        Primary Objectives: To characterize the safety and tolerability of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589) and to identify recommended doses and schedules for future studies Secondary Objectives: To characterize changes in the immune infiltrate in tumors To further characterize the safety of PDR001 in combination with LCL161, everolimus or panobinostat (LBH589) To estimate the anti-tumor activity of PDR001 in combination with LCL161, everolimus or panobinostat (LBH589) To characterize the pharmacokinetics of all study drugs in combination To assess immunogenicity of PDR001
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS#...
        Protocol No.
        HSC20150891HU
        Official Title
        Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS# 15-2139)
        Description
        The overall purpose of this study is to determine the overall response rate, efficacy and safety of the combination of eribulin and Lenvatinib.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Prognostic and predictive markers in patients with advanced metastatic tumors
        Protocol No.
        HSC20130219H
        Official Title
        Numeration and Single-Cell Molecular Profiling of Circulating Tumor Cells as Prognostic and Predictive Marker In Patients with Advanced Metastatic Tumors (CTRC#13-0001)
        Description
        This study will research possible associations between circulating tumor cells (CTC) quantities or gene profile characteristics and clinical outcomes. The primary objective is to obtain blood samples from participants over an 8-week period for research analysis.  The study will enroll approximately 200 patients at the CTRC. In addition to other conditions for enrollment, eligible patients have advanced metastatic cancer.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   RADICAL CYSTECTOMY COMPARED WITH CHEMORADIATION FOR MUSCLE INVASIVE BLADDER...
        Protocol No.
        HSC20150620HU
        Official Title
        RADICAL CYSTECTOMY COMPARED WITH CHEMORADIATION FOR MUSCLE INVASIVE BLADDER CANCER: A PILOT RANDOMIZED CONTROLLED NON-INFERIORITY TRIAL
        Description
        Our study will be a pilot, prospective, single-center, randomized trial to determine the feasibility and patient acceptability of a randomized trial of radical cystectomy versus Combined-modality treatment (CMT) in bladder cancer and to determine compliance rates with assigned treatment. Patients diagnosed with muscle invasive bladder cancer after transurethral resection of bladder tumor and are surgical candidates will be randomized to either radical cystectomy (with neoadjuvant chemotherapy if suitable candidate) or combined modality treatment with chemotherapy and radiation therapy. Both treatment methods are considered ¿standard of care¿ recommended by the NCCN Clinical Practice Guidelines (http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf) in treating bladder cancer, pending on the performance status and comorbidities of the patients.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Repository for Bladder and Genitourinary Cancer
        Protocol No.
        HSC20120159H
        Official Title
        Repository for Bladder and Genitourinary Cancer
        Description
        The primary objective of this repository is to collect and store specimens from patients with suspicion of or diagnosed with bladder cancer.  These specimens will be used to determine the local and systemic immune profiles of patients with bladder cancer.
        Contact
        210-450-0507
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   S1314, A Randomized Phase II Study of Co-Expression Extrapolation (COXEN)...
        Protocol No.
        HSC20150027XT
        Official Title
        S1314, A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer (CTMS #14-2007)
        Description
        To characterize the relationship of DDMVAC- and COXEN scores in terms of pTO rate at cystectomy in patients treated with neoadjuvant chemotherapy. This will be done in two ways: ¿ By assessing whether the treatment-specific COXEN score is prognostic of pTO rate or s; pT1 in this patient population and to assess in a preliminary fashion whether the COXEN score is a predictive factor distinguishing between these two chemotherapy regimens. ¿ By evaluating the correlation between the GC- and the DDMVAC-COXEN score.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain...
        Protocol No.
        HSC20170087HU
        Official Title
        S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer (CTMS# 16-0138)
        Description
        Primary Objectives To compare whether time to high-grade recurrence (TTHGR) for patients with BCG-naive, non-muscle invasive bladder cancer (NMIBC) receiving Tokyo-172 BCG strain (Arm 2) is non-inferior to patients receiving BCG LIVE (TICE® BCG) strain (Arm 1). To test whether TTHGR for patients with BCG-naive, NMIBC receiving intradermal Tokyo-172 BCG vaccination followed by intravesical Tokyo-172 BCG instillation (Arm 3) is superior to patients receiving intravesical Tokyo-172 BCG instillation without prior intradermal BCG vaccination (Arm 2). Secondary Objectives To compare time to recurrence (TTR) with any-grade (AG) bladder cancer between: 1. Patients receiving Tokyo-172 versus BCG LIVE (TICE® BCG) strain, 2. Patients receiving intradermal + intravesical versus intravesical only Tokyo-172 BCG. To compare progression-free survival (PFS) between: 1. Patients receiving Tokyo-172 versus BCG LIVE (TICE® BCG) strain, 2. Patients receiving intradermal + intravesical versus intravesical only Tokyo-172 BCG. c. To compare 6-month complete response in patients with Carcinoma in situ (CIS) present at baseline with or without Ta or T1 cancer receiving: 1. Tokyo-172 versus BCG LIVE (TICE® BCG) strain, 2. Intradermal + intravesical versus intravesical only Tokyo-172 BCG.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   S1609, Dart: Dual Anti-CTLA-4 and Anti-PD-1 Blockage in Rare Tumors (CTMS#...
        Protocol No.
        HSC20170145HU
        Official Title
        S1609, Dart: Dual Anti-CTLA-4 and Anti-PD-1 Blockage in Rare Tumors (CTMS# 17-0013)
        Description
        Primary Objective To evaluate the RECIST 1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. Secondary Objectives To evaluate toxicities in each cohort. To estimate overall survival (OS), progression-free survival (PFS), clinical benefit rate; and to estimate immune-related ORR (irORR), and immune-related PFS (irPFS) by unidimensional immune-related response criteria. To collect specimens for banking for use in future correlative biomarker research studies.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Safety, Tolerability & PK of KX2-361 in Subjects with advanced malignancies...
        Protocol No.
        HSC20150481HU
        Official Title
        A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KX2-361 in Subjects with Advanced Malignancies that are Refractory to Conventional Therapies (CTMS# 15-2063)
        Description
        Study Objectives: Primary Objective: To define the maximum tolerated dose (MTD) of KX2-361 in subjects with advanced refractory malignancies when administered as single and multiple oral doses. Secondary Objectives: To determine the safety and tolerability of KX2-361 after single and multiple oral doses, in subjects with advanced refractory malignancies. To characterize the pharmacokinetic profile of KX2-361 after single and multiple oral doses. To evaluate the activity of KX2-361 in both the Dose Escalation Cohort and the Expansion Cohort of subjects with high-grade glioma.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Study of the Genetic Epidemiology of Childhood Cancer
        Protocol No.
        HSC20080057H
        Official Title
        Study of the Genetic Epidemiology of Childhood Cancer
        Description
        Study of the Genetic Epidemiology of Childhood Cancer
        Contact
        210-562-9123
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Surveillance for low and low-intermediate-risk non-muscle invasive bladder...
        Protocol No.
        HSC20130177H
        Official Title
        Surveillance for low and low-intermediate-risk non-muscle invasive bladder cancer: A Pilot Study (CTRC#12-0108)
        Description
        This is a two-arm, randomized-controlled pilot study with 2 year duration. The "intervention" refers to surveillance based on the EAU guidelines and the "control" refers to surveillance based on the AUA guidelines. Research methods: Participants who presents with non-muscle invasive bladder cancer and meets the inclusion/exclusion criteria will be given an option to participate in the study. Participants will be enrolled at the Urology Clinics at the University of Texas Health Science Center San Antonio (UTHSCSA) Medical Arts and Research Center (MARC) and South Texas Veterans Health Care System (STVHCS). Non-local site include the University of Texas Southwestern Medical Center (UTSW). The research procedures consist of urine collection, cystoscopy, and patient satisfaction and cost questionnaires. The evaluation will be done by the tumor recurrence and progression of the disease. At various time points throughout the study, urine may be obtained from the patient and banked in the Genitourinary (GU) Tissue Bank. Subjects asked to provide a urine sample(s) will be asked to sign a separate informed consent. The urine is de-identified in the lab per the Health Insurance Portability and Accountability Act (HIPAA) protocol GU Tissue Bank Institutional Review Board (IRB) # 20050234H). Patients will undergo cystoscopy in clinic (standard of care). In the intervention arm, patient surveillance cystoscopy will be performed at 3, 12 months and again at 24 months following the diagnosis of bladder cancer. Patients randomized to the control arm, will undergo surveillance cystoscopy every 3 months for 2 years following the diagnosis of bladder cancer. Because use of cytology is variable among the participating urologist, the utilization of cytology will be at the treating urologist''s discretion as per usual standard care. Study duration will be 2 years from most recent biopsy. Patients will be placed on the surveillance schedule based on the length of time from their last tumor.
        Contact
        210-450-0507
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

  •   Healthy Subjects Needed

    •   Immune Tests in Blood to Study Estrogens and Immune Co-Signal Effects on...
      Protocol No.
      HSC20110472H
      Official Title
      Immune Tests in Blood to Study Estrogens and Immune Co-Signal Effects on Immune Function in Age
      Description
      This study will help understand why immunity differs between men and women and how differences change over time. These data will help understand why women are more prone to autoimmunity, and how to use immune therapy effectively in different age groups and sexes. We will also test specific immune defects seen in mouse models of autoimmunity and cancer to determine if these defects also occur in humans.
      Contact
      450-1439
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Canary Prostate Active Surveillance Study (PASS)
      Protocol No.
      HSC20080303H
      Official Title
      Canary Prostate Active Surveillance Study (PASS)
      Description
      All care participants receive is Standard of Care for Active Surveillance.  Research procedures include blood draw every 6 months for serum and plasma, urine collections, prostate tissue collection, Food & Supplement Use Questionnaire and the Health-Related Quality of Life Questionnaire.  Purpose of the PASS is to understand how prostate cancer behaves and to find unique biomarkers (substances in blood, urine or tissue which can indicate the presence of cancer) associated with prostate cancer
      Contact
      210-450-0705
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Establishing Community-Based Normal Distributions of Selected Urinary Biomarkers
      Protocol No.
      HSC20110312H
      Official Title
      Establishing Community-Based Normal Distributions of Selected Urinary Biomarkers
      Description
      This research study has been ongoing for 10 years and originally funded by the American Cancer Society.  For the past 3 years it has been funded by the National Cancer institute but with a different focus.  The three goals of this study are: To improve the accuracy of screening tests for the diagnosis of prostate cancer. Identify biomarkers that will predict how aggressive prostate cancer will be.  The tests currently in use for screening for prostate cancer are the PSA blood test and digital rectal examination (DRE) of the prostate.  When either or both of these tests are positive, a tissue biopsy of the prostate is recommended. The third goal is to provide accurate information about how rapidly prostate cancers will become worse.  To accomplish this we will study tissue and blood to identify proteins and genes that are present at high or low levels in prostate cancers that progress slowly versus those that progress more rapidly.
      Contact
      210-567-0178
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Symptom Management in Prostate Cancer Survivors: Cancer-Related Fatigue,...
      Protocol No.
      HSC20130013H
      Official Title
      Symptom Management in Prostate Cancer Survivors: Cancer-Related Fatigue, Quality Of Life and Physical Function in Prostate Cancer Survivors
      Description
      This study is designed as a cross sectional, exploratory pilot study to examine the onset and progression of cancer-related fatigue in prostate cancer patients. The goal of this project is to report the effect of fatigue on quality of life and pilot a novel salivary biomarker to measure fatigue. One hundred men,diagnosed with prostate cancer and 200 men without prostate cancer  will be recruited to participate in this study. Detailed medical and medication history will be reviewed to determine if subjects are eligible to participate in this study.All eligible participants will be recruited to participate in this study. All activities will be done during the patients regularly schedule visit with their oncologist at the CTRC. Each subject will sign an informed consent form indicating their willingness to participate afterwhich they will complete a battery of survey instruments and provide a 4 mL saliva sample. Saliva will be used to assess concentrations of a fatigue biomarkers in this study and banked for future research studies. Total length of time for study participation for each subject should be less than 1 hour.
      Contact
      210-567-0362
      Locations
      UT Health Science Center
      Learn More About This Study